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Lung cancer is the leading cause of cancer deaths worldwide. In the United States alone, lung 
cancer accounts for ~160,000 deaths per year while the five-year survival rate remains stagnant at 
~15%. Lung can be divided into different subsets including small cell and non-small cell lung 
cancer. Lung Adenocarcinoma (ADCA) accounts for over 50% of non-small lung cancer cases. 
Within this subset, KRAS is the most common activating mutation, accounting for ~35% of cases. 
KRAS mutant tumors have remained a largely un-targetable subtype, and a better understanding of 
the signaling pathways involved in the different ADCA subtypes will be necessary for the 
development of therapeutics. Insulin Receptor Substrate-1 (IRS-1) is a signaling adaptor protein 
that interfaces with many of the pathways that are activated in lung cancer, including 
phosphoinositol 3-kinase (PI3K), extracellular signal regulated kinase (MEK/ERK) and Janus 
Kinase (JAK) and Signal Transducer and Activator of Transcription (STAT). The central theme of 
this work is to describe novel roles for IRS-1 in the lung, including its integral role in the interplay 
between tumor cells and the surrounding tumor microenvironment. A key player in this interaction 
is the neutrophil, which can have pro-host and pro-tumor roles. We have found that neutrophils 
present in the tumor microenvironment cause degradation of the intracellular protein IRS-1, which 
in turn increases PI3K pathway activation leading to increased tumor proliferation. Independent 
study of IRS-1 loss with an Irs-1-deficient mouse model showed that Irs-1 loss induces an increase 
in neutrophil recruitment to the tumor. These two observations reveal a self-perpetuating cycle that 
causes increased tumor burden and mortality in mice and humans. Loss of Irs-1 in our Kras mouse 
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model of lung adenocarcinoma induced activated JAK/STAT signaling and induced recruitment of 
immune cells to the tumor. Since neutrophils are essential for protection against invading 
pathogens, an indirect method of stopping this cycle must be used. Inhibiting JAK in our mouse 
model reduced inflammation, which in turn reduced tumor burden and prolonged survival. Overall, 
this work describes a novel role for IRS-1 as a mediator of cell growth and immune cell 
recruitment in lung adenocarcinoma.   
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1.0  INTRODUCTION 
1.1 LUNG CANCER 
1.1.1 Lung Cancer Statistics 
Lung cancer continues to be the leading cause of cancer deaths worldwide [1]. In the United 
States, lung cancer accounts for 29% of male and 26% of female cancer deaths, totaling 
~160,000 deaths per year. [2] Although in most western countries lung cancer death rates are 
decreasing, many Asian and African countries have increasing lung cancer rates due to recent 
changes in smoking prevalence [1]. In most developed countries, the five-year survival rate is 
less than 18% for women and less than 14% for men [3]. In developing countries, the five-year 
survival rate is only around 9% [3]. The recent decline in lung cancer deaths in Western 
countries is due to reduced smoking rates and not medical or scientific advancements for this 
disease, so continued research is necessary to better treat patients with this disease. 
1.1.2 Brief History of Lung Cancer 
The history of lung cancer is characterized by the emergence of a formerly extremely rare 
disease during the 20th century and its link to cigarettes. In the late 1800’s lung cancer was noted 
to account for only 1% of cancers [4]. That number increased to 10-14% in the early 1900s and 
today accounts for more than 25% of cancers [2, 4]. The invention of the automated cigarette 
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machine in 1876 and World War I were major contributors to the increase in smoking 
prevalence. It is now accepted that cigarette smoke is the leading cause of lung cancer cases. 
This acceptance, however, took decades. The initial suspected agents of lung cancer were 
industrial air pollution, gas exposure from the war and mines, influenza and the least of these 
possibilities, smoking [2, 4]. Population studies of lung cancer and animal experiments 
beginning in the 1930’s started to shed light on the link between cigarette smoke and cancer [4]. 
Unfortunately, for several decades cigarette use continued to rise as tobacco companies 
continued to market cigarettes and downplay potential harm. The Surgeon General’s report of the 
hazards of cigarettes related to lung cancer was released in 1964 [4, 5]. Since the release of this 
report, smoking prevalence in the U.S. has decreased from 42% to 18% in 2012 [5]. Even with 
this decline, 5.6 million people currently under the age of 17 are expected to die from smoking-
related causes later in life [5]. Although awareness of smoking dangers and decline in use has 
had significant improvements, the negative consequences arising from past and current use will 
carry on for decades.  
While most lung cancer cases are smoking-related, there is a subset that occurs in non-
smokers. Worldwide, 25% of lung cancer cases are non-smokers and in western countries about 
10-15% [6, 7]. The statistics vary based on ethnicity and gender. Southeast Asian women have a
higher prevalence, whereas, Western men have a lower prevalence of non-smoker lung cancer 
[7]. There are also differences in the types of lung cancer that non-smokers get. Non-small cell 
lung cancer, specifically adenocarcinoma, is the most common type in non-smokers [7]. The 
study of lung cancer in non-smokers has only begun in the past few years and the exact causes 
are still under investigation. Some of the suspected causes are: air pollution, smoke from cooking 
oil, radon, family history, history of tuberculosis, COPD, emphysema, chronic bronchitis, 
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hormone replacement and second hand smoke [7]. A number of genetic alterations also occur in 
non-smoker lung cancer cases including EGFR, ALK, KRAS, HER2, BRAF, and PIK3CA 
mutations [7].   
1.1.3 Lung Cancer Pathology 
Lung cancer is a heterogeneous disease that consists of two different subtypes: small-cell lung 
cancer (SCLC) and non-small cell lung cancer (NSCLC) making up 15% and 85% of cases 
respectively [8]. NSCLC is further divided into adenocarcinoma and squamous cell carcinoma 
subtypes. There has been a recent push among surgical pathologists to better classify tumor 
subtypes in patients because molecular-targeted therapies have been found to be effective in 
specific subtypes [9]. Two of the most common oncogenic drivers in lung ADCA are Kirsten rat 
sarcoma viral oncogene homolog (KRAS) and epidermal growth factor receptor (EGFR) [10]. 
Whereas EGFR-mutant patients have experienced modest improvement with therapy, KRAS-
mutant tumors remain largely un-targetable [11]. To date, there are only a small number of FDA-
approved targeted agents for NSCLC including bevacizumab (angiogenesis inhibitor), 
pemetrexed (chemotherapy drug), and erlotinib (EGFR inhibitor) [12-14]. The development of 
the tyrosine kinase inhibitor erlotinib, which targets EGFR has provided patient improvement in 
disease progression [12]. Other targeted agents including inhibitors of MEK and AKT pathways 
have provided less than 20% response rates in lung cancer patients [11]. There are a number of 
therapies currently in phase II and III clinical trials that target VEGFR, PDGFR, KIT, IGF-IR 
and EGFR. Unfortunately, there are still no targeted treatments for KRAS mutant patients.  
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1.2 INFLAMMATION AND CANCER 
1.2.1  Inflammation and Cancer 
The history of immunology has been characterized by competing pro-host versus anti-host 
theories. The field continues to evolve today as it is extended to investigation of tumor initiation 
and progression. In the early stages of immunology around the mid-1800’s, it was observed that 
immune cells were present alongside bacterial cells and thus thought to have a pro-bacteria 
function [15]. This theory was challenged by Metchnikoff in the late-1800’s to early-1900’s, 
who’s work was the first description of the phagocytic abilities of immune cells, providing a pro-
host role for immune cells against infectious agents [16-18]. This same paradigm shifting 
development has begun in recent decades with regard to the role of inflammation and cancer. 
The first description of a link between inflammation and cancer was by Rudolf Virchow in 1863 
when he noted leukocytes in neoplastic tissue and suggested that inflammation plays a role in the 
development of cancer [19, 20]. In the early 1900’s Ehrlich proposed the theory that the immune 
system could eliminate cancers [21]. In the 1960’s and 1970’s Burnet and Thomas developed the 
theory of cancer immunosurveillance in which the immune system protected against tumor 
formation [22, 23]. Unfortunately, this theory was abandoned for more than twenty years based 
on experiments with a newly developed athymic nude mouse that showed no difference in tumor 
initiation and growth based on the immune system [21]. The development of knockout mice in 
the 1990’s brought back interest in the immunosurveillance theory. Studies involving the loss of 
different immune cells and cytokines indicated the importance of the immune system in 
eliminating cancer formation [21]. Another line of thinking developed in the early 2000’s as 
epidemiological studies gave evidence that chronic inflammation was related to an increase in 
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tumor development [24, 25]. It is now thought that acute inflammation can eliminate early cancer 
and chronic inflammation induces cancer development [26]. 
An important emerging concept in cancer biology is the role of the tumor 
microenvironment in tumor progression. Immune cells represent an important component of the 
tumor microenvironment. It has become evident that inflammatory responses increase tumor 
initiation and progression. Immune cells supply the tumor with different factors including growth 
factors, cytokines and reactive oxygen species that promote proliferation, survival, angiogenesis, 
invasion and metastasis [26-28]. Chronic inflammatory diseases have been correlated with 
development of cancers [19, 24, 26, 28]. Recent research has confirmed this observation, as 
many cancers are associated with chronic inflammation due to bacterial or viral infection and 
chemical and physical agents [19].   
1.2.2 Neutrophils and Cancer 
Neutrophils are a subset of leukocytes that are essential for protecting the host against invading 
pathogens [29]. They are the first line of defense against bacteria, fungi, protozoa, viruses [29]. 
Neutrophils are phagocytes that also release cytotoxic substances as well as proteinases into the 
extracellular environment. While this release is protective against pathogens, it also can cause 
damage of normal surrounding tissue [30]. Neutrophils are produced in the bone marrow where 
they are pre-packaged with granulocytic factors including proteinase-3, cathepsin G and 
Neutrophil Elastase and then are released into circulation with a life span of 1-3 days [29, 31]. 
Neutrophil Elastase is a major component of neutrophil function. It is released during 
degranulation and has a wide array of proteolytic activity against proteins and extra-cellular 
matrix components including elastin [32].  
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Neutrophils are capable of supplying the tumor with different factors including growth 
factors, cytokines and reactive oxygen species that promote proliferation, survival, angiogenesis, 
invasion and metastasis. [26-28]. An important observation in many cancer types, including 
NSCLC, is that elevated blood and intra-tumoral neutrophil counts correlate with poor patient 
outcomes [33]. Many of the trials providing evidence for this have only been published in recent 
years and it is still unclear how to use this observation to direct treatments in patients. Depleting 
neutrophils systemically could have severe negative consequences, as patients would become 
immune-compromised and susceptible to infection [30].  
1.3 INSULIN RECEPTROR SUBSTRATE-1 
1.3.1 Discovery of Insulin Receptor Substrate-1 
The history of Insulin Receptor Substrate-1 (IRS-1) begins with a once fatal disease, diabetes. 
Diabetes first became a recognized disease in the early 1800’s, and at this time patients had only 
weeks to live from time of diagnosis [34]. Almost 100 years later, it was discovered that insulin 
extracted from the pancreas could extend the lives of patients [35, 36]. Diabetes currently affects 
almost 27% of people over the age of 65 [34]. Insulin signaling has been a highly investigated 
field over the past several decades and many advancements have been made, including the 
development of synthetic insulin, characterization of the two different types of diabetes, as well 
as a thorough understanding of the cellular signaling cascade involved [34, 37, 38]. The intense 
study of insulin signaling has also revealed its role in cellular development, growth and 
metabolism [37]. The 3-dimensional structure of the insulin receptor was discovered in 1969 
[39]. In 1985, Insulin Receptor Substrate-1 was identified as a 185 kD protein that becomes 
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phosphorylated due to cellular stimulation with insulin [40]. With the successful cloning of IRS-
1 in 1991, it was then determined that IRS-1 coordinates signaling between the insulin receptor 
and PI3K [41]. To better understand the role of IRS-1 in signaling, an Irs-1 null mouse was 
engineered. This mouse had low birth weight, displayed hyperglycemia and was insulin-resistant 
[42]. The development of this mouse precipitated the discovery of a related protein that had 
overlapping functions with IRS-1; it was named Insulin Receptor Substrate-2 (IRS-2) [42, 43]. 
An Irs-2 null mouse was then engineered and this mouse displayed normal adult weight and 
development of type 2 diabetes [44]. An immense body of knowledge has since been added to 
the literature describing IRS protein signaling. The majority of research done on IRS proteins 
has, however, been in the setting of glucose metabolism and diabetes in metabolically active 
tissues such as muscle and adipose tissue.  
1.3.2 Insulin Receptor Substrate-1 (IRS-1) Signaling 1 (Adapted from Metz, et al. Clinical 
Cancer Res, 2011.) 
Insulin receptor substrates (IRS) are signaling adaptor proteins that function as intermediates of 
activated cell surface receptors, most notably for the insulin receptor (IR) and insulin-like growth 
factor receptor (IGF-IR) [41, 43, 45]. More recently, IRS proteins have been shown to signal 
downstream of integrin, cytokine, and steroid hormones receptors as well [46, 47], although 
these functions are poorly understood when compared with the “canonical” (IR- and IGF-IR–
mediated) properties of IRS proteins. By mediating the activities of these receptors, IRS proteins 
interface with several signaling pathways, thereby impacting numerous aspects of cell behavior, 
including metabolism, motility, survival, and proliferation (Fig. 1). The majority of IRS protein 
research to date has centered upon the study of glucose metabolism and the pathogenesis of 
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diabetes. Reports pertaining to the roles of IRS proteins in cancer progression are beginning to 
emerge [48]. 
Six IRS proteins have been described; however, IRS-3 is expressed only in rodents [49], 
IRS-4 displays limited tissue expression (brain and thymus; [50]), and IRS-5 and IRS-6 are 
structurally dissimilar from the others [51]. Therefore, most of the attention has been focused on 
IRS-1 and IRS-2, both of which are widely expressed. IRS proteins share similar structural 
domains including an N-terminal pleckstrin homology domain and a phospho-tyrosine binding 
(PTB) domain, which is required for binding NPEY motifs in the juxtamembrane region of 
ligand-activated IR and IGF-IR [52]. The carboxy terminus contains numerous serine and 
tyrosine phosphorylation sites that bind PTB containing src-homology-2 (SH2) proteins, 
including p85, Grb2, Nck, the phosphotyrosine phosphatase SHP2, Fyn, and others [53]. 
Although IRS proteins are not catalytically active, they are capable of impacting numerous 
signaling cascades via interaction with SH2 proteins.  
Despite sharing binding partners and structural similarities, IRS-1 and IRS-2 functions 
are not entirely overlapping. IRS-1−/− mice display low birth weight and glucose intolerance, but 
do not develop overt diabetes [42]. The generation of these mice led to the discovery of IRS-2, 
which was believed to compensate for the loss of IRS-1 and prevent additional metabolic 
derangements. IRS-2−/− mice have subsequently been shown to develop diabetes as a 
consequence of decreased β-cell function and insulin resistance [44]. Therefore, IRS-1 and IRS-2 
possess both overlapping and unique properties, although their relative contribution to cancer 
growth and invasiveness has yet to be elucidated.  
Though IRS proteins signal through many pathways, their predominant function seems to 
be activation and/or regulation of the phosphoinositide 3-kinase (PI3K) and extracellular signal 
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regulated kinase (ERK) pathways. PI3K is a heterodimer with separate regulatory (p85) and 
catalytic subunits (p110). In its resting state, PI3K exists as an inactive p85-p110 complex. Upon 
the activation of a receptor tyrosine kinase (RTK), meaning phosphorylation of its cytoplasmic 
tail, the p85-p110 complex is recruited to the receptor by interaction of an SH2 domain on p85 
with phosphotyrosine residues on the RTK [54]. This interaction is believed to release the 
inhibitory effects of p85 on the catalytic p110 [55]. p110 is now able to interact with its lipid 
substrates, the phosphatidylinositols, and convert PIP2 to PIP3. Recruitment of PI3K by RTK 
also puts p110 in close proximity to these lipid substrates residing in the plasma membrane. The 
major exception to this schema is that PI3K can be activated by signal adapter proteins, such as 
IRS-1 and IRS-2, rather than by RTKs themselves [47]. Of note, IRS-mediated activation of 
PI3K requires that phosphorylated YMXM motifs occupy both SH2 domains within p85 [56].  
Generation of PIP3 by activated PI3K near the plasma membrane results in interaction 
with, and subsequent phosphorylation of, its primary substrate, Akt [57]. Once activated, pAkt 
uses extensive downstream signaling pathways to enhance tumor viability in one of three ways: 
cell survival, cell proliferation (number), and cell growth (size; [58]). The avoidance of 
apoptosis, achieved by the direct phosphorylation of BAD by pAkt, is generally considered the 
predominant function of PI3K/Akt in cancer cells . However, PI3K/Akt also promotes tumor cell 
proliferation by causing an accumulation of cyclin D1, which regulates G1/S phase transition 
[59]. This is accomplished by inhibition of p27, p21, and glycogen synthase kinase-3β (GSK3β), 
which target cyclin D1 for proteasomal degradation, when active [60, 61].  
PI3K activity seems to be regulated in two ways. The first is simply the activation of the 
p85 subunit, which maintains p110 in an inactive state at baseline. The second is the 
constitutively active negative repressor, phosphatase and tensin homolog (PTEN). PTEN 
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regulates the output of PI3K by dephosphorylating PIP3 back to PIP2 [62]. Mutation in PTEN is 
relatively common in cancers, and has been linked to PI3K hyperactivity in several, including 
prostate carcinoma, hepatocellular carcinoma (HCC), melanoma, renal-cell carcinoma, and 
glioblastoma, among others [63-67]. Interestingly, PTEN mutation is rare in some cancers, 
including lung cancer [68]. The common explanations for PI3K hyperactivity in the setting of 
preserved PTEN expression has been activation of PI3K by K-ras and genetic mutations within 
the PI3K pathway (e.g., PIK3CA), both of which possess the ability to by-pass regulatory 
machinery [69-71].  
Although generally considered positive effectors of growth factor, IRS proteins may, in 
fact, function as homeostatic regulators of PI3K output in certain tissues. Supporting evidence of 
this theory includes the fact that IRS-p85 interaction takes place within the cytosol, pulling PI3K 
away from its lipid substrates and creating compartmentalization phenomena for signaling [72]. 
Furthermore, IRS proteins display low potency for ligand interaction. As an example, IRS-1-
Grb2 binding results in nearly 10-fold less pathway output when compared with other common 
Grb2-binding partners [73].  
1.3.3 Pro-Host and Pro-Tumor Roles for IRS-1 (Adapted from Metz, et al. Clinical 
Cancer Res, 2011.) 
Preclinical studies have shown both protumor and prohost functions for IRS proteins in cancer. 
IRS-1 overexpression has been shown to induce malignant transformation in both embryonic 
mouse fibroblasts [74] and NIH3T3 fibroblasts [75, 76]. Such cells are capable of tumor 
formation in nude mice, a process displaying MEK/ERK hyperactivity and requiring IGF-IR, as 
embryonic fibroblasts derived from IGF-IR−/− mice are resistant to IRS-1–induced 
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transformation [77]. Oncogenic transformation by IRS-1 has not been described for other cell 
types.  
Both IRS-1 and IRS-2 are commonly overexpressed in HCC, which is characterized by 
IR and IGF-IR signaling hyperactivity [78, 79]. IRS-1 overexpression in HCC cell lines prevents 
TGF-β–induced apoptosis [80]. In fact, transfection of these cells with a dominant-negative IRS-
1 reverses their malignant phenotype [81].  
The role of IRS-1 in breast cancer has been difficult to elucidate, as both prohost and 
protumor functions have been described. Simple overexpression of IRS-1 in MCF-7 breast 
cancer cells accelerates their growth, whereas IRS-1 gene silencing ultimately results in 
apoptosis, at least under serum-free conditions [82, 83]. IRS-1 and IRS-2 transgenic mice both 
display enhanced tumor growth, metastasis, and resistance from apoptosis [84]. These mice 
develop mammary gland hyperplasia early in life, and display unusual tumor histology, and not 
the typically encountered adenocarcinoma [85]. Thus, these overexpression studies may not be 
representative of pathophysiologic properties of IRS proteins in human cancers. As such, IRS-1–
silenced tumor xenografts actually displayed increased metastasis [86], consistent with a prohost 
role for IRS-1. Additionally, studies of IRS-1 in human breast cancer show that IRS-1 expression 
is lost in clinically advanced cases [87].  
We have recently described a prohost role for IRS-1 in lung cancer [88]. While 
investigating the role of neutrophil elastase in lung cancer, we observed that neutrophil elastase–
deficient tumors in the Lox-Stop-Lox-K-ras (LSL-K-ras) model of lung adenocarcinoma [89] 
accumulated intracellular IRS-1 protein, whereas neutrophil elastase–sufficient tumors contained 
scant IRS-1. We were able to show that IRS-1 is an intracellular proteolytic target for neutrophil 
elastase, which induced cellular proliferation and pAkt production upon the degradation of IRS-
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1. Ultimately, we discovered that the loss of IRS-1 functioned to increase the pool of bio-
available PI3K, rendering p85 free to interact with the more potent growth factors present in lung 
cancer cells, especially the platelet-derived growth factor (PDGF) and receptor (PDGFR) 
complex [90]. Consistent with this concept, IRS-1 gene silencing in lung cancer cells resulted in 
cellular proliferation and pAkt production, whereas IRS-1 overexpression induced cell cycle 
arrest. Furthermore, a correlation of the presence of neutrophil elastase with the absence of IRS-1 
was established in human lung adenocarcinomas. Thus, IRS-1 is capable of both growth 
promoting and growth regulatory functions in cancers, depending on the cell of origin.  
Figure 1. IRS-1 signaling. (Metz, et al. Clinical Cancer Res, 2011.): IRS-1 regulates downstream 
signaling of IR/IGF-IR. IRS-1 is a homeostatic regulator of PI3K signaling in lung tumor cells. 
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IRS-1 has serine and tyrosine phosphorylation sites that bind SH2 domain–containing proteins 
including p85, Grb2, and SHIP2, among others. IRS-1 recruits PI3K and MEK/ERK via 
interaction with the regulatory p85 subunit and GRB2, respectively. The catalytic subunit of 
PI3K, p110, is now available to convert PIP2 to PIP3. PIP3 activates PDK-1, which subsequently 
phosphorylates AKT, enhancing cell survival, proliferation, and growth. Downstream effectors 
of AKT inhibit apoptosis via inhibition of Bad, Bim, Bax, and caspase 9, and activation of BCL-
XL and Bcl-2. Tumor cell proliferation is promoted by the inhibition of GSK3, which targets 
cyclin D1 for proteasomal degradation. Increased protein synthesis results from activation of the 
mTOR pathway. The MEK/ERK pathway also promotes proliferation via interaction of IR/IGF-
IR with IRS or Shc proteins. A feedback loop exists between the PI3K/AKT signaling pathway 
and IRS-1, in which IRS-1 is degraded through the ubiquitin-proteasome degradation pathway. 
The above pathways have been well established in metabolically active tissues including adipose 
and muscle. The above figure, however, describes an alternative to those established paradigms. 
In lung cancer cells, the PI3K/AKT pathway is weakly activated by IRS-1. IRS-1 acts 
homeostatically to prevent activation of PI3K by more potent mitogens, including PDGF. 
Therefore, the loss of IRS-1 increases the amount of available PI3K, which can then be activated 
by these mitogens causing much greater pathway activation. As shown, neutrophil elastase (NE) 
can enter tumor cells and degrade IRS-1 during tumor-associated neutrophilic inflammation 
allowing other RTKs to control PI3K signaling.  
1.3.4 IRS-1 Mouse Model 
A second generation Irs-1 null mouse was engineered a few years after the original IRS-1 
knockout mouse. This new mouse was designed with an Irs-1 gene flanked by two loxP sites, 
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allowing for its targeted removal in specific tissues [91]. LoxP sites are the target of an 
Adenoviral Cre recombinase (Adeno Cre) that removes the gene during a recombination event 
[92]. This mouse model thus presents the opportunity to selectively delete Irs-1 from a specific 
tissue with the administration of AdenoCre. For a lung model, the AdenoCre would be delivered 
either intranasally or intratracheally, directing the virus into the lungs where it would then infect 
the cells of the lung and delete Irs-1. This mouse can also be crossed with other genetically 
modified mice in order to study the effects of combined genetic mutations.   
1.4 JANUS KINASE (JAK) AND SIGNAL TRANSDUCER AND ACTIVATOR OF 
TRANSCRIPTION (STAT) SIGNALING 
1.4.1 JAK/STAT 
It has become clear that Janus Kinase (JAK) and Signal Transducer and Activator of 
Transcription (STAT) signaling play an important role in tumor growth and development [93, 
94]. The JAK/STAT pathway is known for its major role in the initiation and resolution of 
inflammation [93]. The discovery of STATs and JAKs came about through the study of 
interferons, cytokines that mediate signals between host cells and the immune system in response 
to pathogens, in the late 1980’s and early 1990’s by two independent groups [95]. These 
investigators noted that a protein mediator functioned to relay signals from extracellular 
cytokines through cytokine receptors and transmit the signal to the nucleus to induce 
transcription. This protein mediator became known as a STAT. Between the late 1980’s and late 
1990’s several different STATs and JAKs were described [96-102]. Since their discovery, JAKs 
and STATs have been heavily investigated. Studies identified the roles of JAKs and STATs as 
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mediators in immune modulation through cytokine signaling [103]. Aberrant JAK/STAT 
signaling has been found to play a role in tumorigenesis through the modulation of immune 
responses around the tumor site [104]; and currently, several JAK inhibitors are in clinical trial 
[103]. 
1.4.2 JAK/STAT Signaling 
The JAK/STAT pathway is characterized by signaling from extracellular growth factors through 
cell-surface receptors mediating phosphorylation and dimerization of STATs leading to nuclear 
localization of STATs and increased gene expression. Signaling becomes activated through a 
combined interaction between the cytokine receptor, JAK and STAT proteins. The receptor first 
dimerizes and allows for JAK binding and phosphorylation. The activated JAK then induces 
phosphorylation of the receptor providing a site for STAT binding (SH2 site). JAK is then able 
to phosphorylate STAT on a tyrosine residue (around residue 700). Activated STATs form 
dimers and translocate to the nucleus. STAT dimers are transported to the nucleus through 
binding of transportin. The combinations include STAT1: STAT1, STAT3: STAT3, STAT4: 
STAT4, STAT5: STAT5, STAT1: STAT2 and STAT1: STAT3. Tetramer combinations are also 
possible [105, 106]. 
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Figure 2. JAK/STAT signaling: Ligand binding to cytokine receptors triggers activation of JAKs. 
The JAKs then phosphorylate the receptor, which induces recruitment of STATs to the receptor 
which are in turn phosphorylated by JAKs. The STAT molecules then dimerize and are 
transported to the nucleus where they activate transcription.  
There are almost 40 cytokine receptors that signal through the JAK/STAT system [107]. 
One such receptor that has been found to play a role in lung adenocarcinoma is the IL-22 
receptor [108]. The IL-22 receptor consists of a dimer between Il-22R1 and IL-10R2, which is 
activated by the cytokine IL-22 [109]. In the lung, IL-22 predominantly comes from T cells 
including Th1, Th17 and Th22 cells. Release of IL-22 from these cells is driven by IL-6 and IL-
23, whereas TGFB inhibits IL-22 production [109].  
Deregulated JAK/STAT signaling can be found in many different tumor types and 
presents the opportunity for different levels of therapeutic intervention [110]. A meta-analysis of 
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17 clinical trials revealed that STAT3 activation predicts poor outcomes in NSCLC patients 
[111]. Roughly half of lung adenocarcinoma cases have activated STAT3 signaling [112, 113]. A 
study investigating the role of JAK inhibition in different NSCLC cell lines demonstrated its 
growth inhibitory effect in several cell lines but only in 3-dimensional soft agar and xenograft 
assays [114]. This study also demonstrated that STAT3 activation in these cell lines is dependent 
on JAK2 and not on oncogenic drivers and therefore, inhibitors of pathways activated by driver 
mutations may not effectively reduce tumor growth [114]. JAK inhibition may provide a 
promising strategy for treating certain lung cancer patients.  
1.5 KRAS  
1.5.1 Description of KRAS 
Kirsten rat sarcoma (KRAS) is one of the most commonly mutated genes in lung cancer, found in 
about ~30% of lung adenocarcinoma cases [115]. Kras is an oncogene that was first discovered 
as a transforming retrovirus in animals. Ras was first identified in the mid-1960s when studies by 
Harvey and Kirsten showed that a rat leukemia virus induced sarcomas in infected rodents [116, 
117]. These viruses became known as the Harvey murine sarcoma virus (HRAS) and the Kirsten 
murine sarcoma virus (KRAS). Scolnick, in the mid-70’s, showed that these viruses transduced 
normal sequences from the rat genome [118, 119]. In the late 70’s and early 80’s several groups 
studied the role of DNA from transformed cells in animal and human tissue and found that DNA 
had transforming potential [120]. These studies were revolutionary to the field of cancer 
research.  
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There are 3 human RAS genes; H-RAS, N-RAS and K-RAS which all function through 
regulation of GDP/GTP exchange, transmitting signals from extracellular ligands through cell 
surface receptors including RTK’s, non-RTK’s and GPCR’s [121]. The RAS genes are present in 
many different tissue types and have both overlapping and divergent roles [122]. KRAS is the 
most common activating mutation in cancer [123]. RAS is a small GTPase that alternates 
between a GTP-bound active state and a GDP-bound inactive state [124]. Oncogenic RAS 
becomes constitutively activated in the GTP-bound state [123]. This RAS activation then leads to 
increased signaling through RAF/MEK/ERK, PI3K/AKT/mTOR and RalGEF/RAL/NFκB 
pathways [124]. Over-activation of these pathways induces cellular proliferation and increased 
tumorigenesis [124].  
It has become evident that different types of KRAS mutations cause different effects with 
regard to downstream signaling and subsequent cellular behavior. There are a few common 
KRAS mutations, including mutations in codon 12, 13, 10 and 61, with the most prevalent of 
these being a mutation in codon 12 [125]. Recent work has demonstrated that depending on 
which codon is mutated, KRAS toggles between signaling through MEK, AKT or RalA/B and 
that these differences in signaling impact patient survival [126]. Investigation of NSCLC cell 
lines has revealed that mutant-KRAS-G12D mutations signal through AKT and MEK pathways, 
whereas mutant-KRAS-G12C signals through RalA/B and MEK and wildtype KRAS signal 
through MEK [126].  
1.5.2 Kras Mouse Model of Lung Adenocarcinoma 
Several generations of mouse models have been developed to study KRAS mutation [124, 127]. 
In the late 1990’s, the development of a null Kras mouse was attempted. However, it was noted 
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that all offspring were heterozygous for the Kras gene. It was thus found that homozygous 
deletion of Kras is embryonic lethal due to cardiac, neurological, hematological as well as liver 
defects in embryos [122, 128]. It became evident that having a functional Kras gene is necessary 
for development and laid the groundwork for future Kras mouse models. A few years later, a 
mouse model was developed in which a latent form of mutant Kras-G12D was inserted and later 
became active upon spontaneous recombination events [129]. In this model, embryos expressed 
normal Kras to ensure normal development until birth and later developed tumors with the 
accumulation of recombination events inducing mutant Kras expression. These mice most 
notably developed lung tumors that ranged from hyperplasia to adenocarcinoma [129]. The 
disadvantage of this model is non-synchronous tumor initiation and development, which is a 
confounding factor for careful study of tumor growth and development. To address this issue, the 
same group developed a system that would allow for conditional expression of mutant Kras. In 
this system, a Lox-Stop-Lox (LSL-) sequence flanks the K-ras-G12D sequence, preventing its 
expression until activation is desired [89]. An adenoviral Cre recombinase (AdenoCre) is 
administered intranasally to the mouse and upon entry removes the stop codon, allowing for 
expression of the mutant gene. Once activated, mice displayed a progression from atypical 
adenomatous hyperplasia (AAH), epithelial hyperplasia (EH) and finally adenomas in a 
predictable time course based on dose of AdenoCre [89]. The LSL-Kras model has become a 
gold standard for lung cancer research and has since been combined with many other mouse 
models, including ones in which genes are mutated, deleted or overexpressed in order to more 
fully understand the complexities of this disease in a controlled manner.  
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1.6 IDIOPATHIC PULMONARY FIBROSIS (A LUNG CANCER RELATED 
DISEASE) 
1.6.1 Idiopathic Pulmonary Fibrosis Pathology 
Patients with idiopathic pulmonary fibrosis (IPF) are more likely to have lung cancer than non-
IPF patients [130]. IPF is a debilitating disease characterized by scarring of the lung and loss of 
function due to deregulated fibroblast repair response to epithelial injury [131]. IPF is the most 
common interstitial lung disease with only a 3 to 5 year survival rate [132]. The exact 
mechanisms and causes of IPF are still unclear. It is thought that cigarette smoking, viral 
infections and environmental factors such as asbestos lead to the development of IPF [133]. IPF 
is characterized by persistent inflammation and wound healing processes during which 
fibroblasts deposit extracellular matrix causing dense fibrotic tissue accumulation in the lung 
[134]. Sadly, there are currently no effective treatments for IPF [130]. A better understanding of 
the mechanism for development of fibrotic lung tissue will be necessary for the successful 
development of new therapies for this disease.  
1.6.2 Neutrophils and Fibroblasts 
The lungs have resident fibroblasts that function in tissue homeostasis by secreting factors that 
maintain the extracellular matrix. In the setting of wound healing, fibroblasts develop an 
activated phenotype and are called myofibroblasts. These myofibroblasts release matrix 
metalloproteinases that function in tissue remodeling, secrete collagen that leads to scarring and 
express alpha-smooth muscle actin, which allows for its contractile properties [135]. There are 
three phases of would healing that include: an immune response, proliferation of fibroblasts and 
21 
activation to myofibroblasts and finally deposition and remodeling of the extracellular matrix 
[136]. The final phase is point at which scarring can occur. There is some evidence that 
neutrophils can affect fibroblast activity. There is clinical data to suggest that neutrophils and 
Neutrophil Elastase are related to IPF pathology [134]. Further studies into the role of 
neutrophils in fibroblast activation may illuminate this complex disease.  
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2.1 INTRODUCTION 
Lung cancer continues to be the leading cause of cancer deaths worldwide [1]. In the United 
States alone, lung cancer accounts for more than 160,000 deaths per year with five-year survival 
rates of just ~15% [2, 3]. Lung cancer is a heterogeneous disease that is typically subdivided into 
two major subtypes: small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), 
which constitute approximately 15% and 85% of cases, respectively. NSCLC is further sub-
classified by the existence of multiple histologic subtypes, most of which are designated as lung 
adenocarcinoma (L-ADCA, ~60%) or squamous cell carcinoma (L-SCCA, ~20%) [8]. In 
contrast to L-SCCA, L-ADCA is characterized by the presence of driving mutations in key 
oncogenes, such as the epidermal growth factor receptor (EGFR) and the Kirsten rat sarcoma 
viral oncogene homolog (KRAS) [10]. Whereas EGFR-mutant cancers can be addressed with 
novel targeted therapies, KRAS-mutant tumors remain largely un-targetable [11].  
Numerous studies have been performed that address the impact of a specific driving 
mutation on the function of a particular signaling pathway. However, the impact of alterations in 
the signaling pathway machinery within these aberrantly functioning pathways, have not been 
adequately studied. Of the numerous proteins that are involved in pathway signaling, the insulin 
receptor substrate-1 (IRS-1) is somewhat unique in that it interfaces with many different 
pathways, including the phosphoinositol 3-kinase (PI3K) and extracellular signal regulated 
kinase (MEK/ERK) pathways, as well as the JAK/STAT signaling pathway [53, 137-142]. IRS-1 
is afforded this promiscuity as a result of possessing numerous binding domains, including an N-
terminal pleckstrin homology (PH) domain, a phospho-tyrosine binding (PTB) domain and a 
carboxy-terminus with multiple serine and tyrosine phosphorylation sites. IRS-1 is a signaling 
adaptor protein best known for mediating canonical signaling from both the insulin receptor (IR) 
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and the insulin-like growth factor receptor (IGF-IR) [45]. The majority of research investigating 
the function of IRS proteins has naturally been performed in the setting of glucose metabolism 
and diabetes in metabolically active tissues, including muscle and adipose tissue. In this context, 
IRS-1 has been appropriately characterized as a positive effector of growth factor [47, 56]. 
However, the impact of IRS-1 on pathway activity in cancer cells, where aberrant signaling is 
frequently encountered, has not been adequately addressed.  
An emerging concept in cancer biology is the role of the tumor microenvironment (TME) 
on tumor progression, and the role of aberrant pathway signaling in sculpting the TME. Immune 
cells represent a major component of the TME, frequently comprising over half of the cells in 
resected tumor specimens. It has become evident that inflammatory responses increase tumor 
initiation and progression, as immune cells are capable of supplying tumors with the growth 
factors, cytokines, and reactive oxygen species required to promote proliferation, survival, 
angiogenesis, invasion and metastasis [26-28]. The mechanisms by which cancers generate 
tumor-promoting microenvironments must be further explored in order to identify novel 
therapeutic agents that address the TME. 
Given the prominent role of IRS-1 in signaling pathways commonly hyperactive in L-
ADCA, we undertook an independent study of this protein within the adenocarcinoma subtype. 
Surprisingly, we identified a counter-paradigmatic and pro-host role for IRS-1 specifically in 
KRAS mutant L-ADCA via alterations in cancer cell signaling that subsequently impacted the 
cellular composition of the TME.  
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2.2 MATERIALS AND METHODS 
2.2.1 Mice 
Lox-Stop-Lox-K-ras (LSL-K-ras) and Irs-1fl/fl (Morris White, Boston Children’s) mice on a pure 
SVEV background (backcrossed >10 generations) were used in these studies. The mice were 
housed in a pathogen free barrier facility at the Fred Hutchinson Cancer Research Center 
(FHCRC) and experiments were performed in accordance with approved IACUC protocols.  
2.2.2 Intratracheal administration of AdCre 
A titer of 4x107 pfu AdCre (University of Iowa Viral Vector core) was administered 
intratracheally (IT) to sex-matched anesthetized mice between 8 and 10 wks of age via a 22g 
intravenous (IV) catheter placed in the trachea. 
2.2.3 Assessment of mortality 
LSL-K-ras/Irs-1+/+ and LSL-K-ras/Irs-1fl/fl mice (n>25 per group) were followed from the date of 
AdCre administration until death or signs/symptoms of impending mortality.  This time interval 
was used to calculate overall survival. Differences in survival were measured using the Kaplan-
Meier method. 
2.2.4 BAL fluid analysis 
At 8, 12 and 16 weeks post-AdCre, mice were sacrificed and bronchial alveolar lavage (BAL) 
fluid was collected by inserting a 22g IV catheter into the trachea. Lungs were then lavaged with 
0.75ml saline 4 times. The BAL fluid was centrifuged at 3,000 r.p.m. for 3 minutes. Red blood 
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cells (RBC) were lysed using a RBC lysis buffer (Biolegend, San Diego, CA). Total cell counts 
were obtained using a hemocytometer. Cytospins were made from each suspension and manual 
differentials were generated using Hema-3 staining (Thermo Fisher Scientific, Waltham, MA).  
2.2.5 Histology and immunohistochemistry  
At 8, 12 and 16 weeks post-AdCre, the mice were sacrificed and the lungs were harvested. A 
split lung inflation technique was performed in which the left lung was ligated, removed and 
frozen, while the right lung was subsequently inflated with 2X Zinc Fixative (BD Biosciences 
#552658, San Diego, CA) at 25cm H2O pressure via intratracheal catheter for 15 minutes. Lungs 
were removed and fixed in 2x Zinc Fixative for 72 hours. Lungs were then paraffin embedded. 5-
µm paraffin-embedded sections were stained for hematoxylin and eosin (H&E), IRS-1 (abcam 
#52167, Cambridge, MA), Ly-6G (Biolegend #127601, San Diego, CA), Phopho-Stat3 
(pTyr705) (D3A7) (Cell Signaling # 9145, Danvers, MA), and IL-22 receptor alpha 1 (IL22RA1) 
(Millipore # 06-1077, Temecula, CA). Staining was preformed using the avidin-biotin HRP 
technique with 3,3′-diaminobenzidine (DAB) as the chromogenic substrate as previously 
described [143]. 
Slides were scanned using Eclipse 80i microscope (Nikon Instruments Inc., Melville, 
NY). Total lung and tumor area was determined from H&E stained slides using NIS-Elements 
Advanced Research software (Nikon). Tumor area % was calculated as follows: ((tumor area/ 
total lung area) x 100). Phospho-Stat3 and IL22RA1 stained lung tissue were scored using a grid 
at 40X magnification. Results are expressed as number of positively stained cells per high-
powered field (hpf) from a total of 5 hpf per slide.  
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2.2.6 Therapeutic studies in mice 
Mutant K-ras expression was induced in LSL-K-ras and LSL-K-ras/Irs-1fl/fl mice using AdCre, as 
described above. After allowing 8 wks post-AdCre for tumors to develop, mice (n=8 per group) 
received either the JAK inhibitor AZD1480 (30 mg/kg) (AstraZeneca) or vehicle control via oral 
gavage. Mice were treated with drug or vehicle 6 days per week for 3 weeks. In a separate 
experiment, LSL-K-ras/Irs-1fl/fl mice were treated with either the neutrophil-depleting Ly-6G 
1A8 monoclonal antibody or Rat IgG2a 2A3 isotype control (BioXCell, West Lebanon, NH) 
beginning at 6 wks post-AdCre for 4 weeks at a dose of 500µg 3 times per week. 
2.2.7 Quantitative PCR (qPCR) 
Frozen mouse lungs were homogenized in Trizol (Invitrogen, Carlsbad, CA) and total RNA was 
extracted using chloroform and isopropanol precipitation. cDNA was generated from 2µg total 
RNA using a SuperScript cDNA synthesis kit (Invitrogen, Carlsbad, CA). qPCR was performed 
using a StepOnePlus Real-Time PCR Machine (Applied Biosystems) and Taqman primer/probe 
sets (Applied Biosystems). Reactions were run in triplicate and GAPDH was used as the 
endogenous housekeeping gene. Delta-CT values were used for data analysis and expressed as 
fold change from control.  
2.2.8 Cells 
A549 (ATCC # CCL-185) and 201T (Obtained from University of Pittsburgh Cancer Institute 
[144]) human lung adenocarcinoma cell lines were used for in vitro experiments. Cells were 
maintained in Dulbecco’s modified essential medium (DMEM) plus 10% fetal calf serum (FCS) 
and 1x penicillin-streptomycin (Gibco). 
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2.2.9 shRNA transfection 
A549 and 201T cells were transfected with control and IRS-1 Lentiviral Transduction particles 
(Sigma-Aldrich SHC001V and TRCN0000039910 NM_005544.1-4044s1c1). Cells were plated 
in 96-well plate (4,000 cells per well) in DMEM containing 10% serum and allowed to adhere 
overnight. 5 μl of transduction particles were added to each well for 18 hours. Plates were 
washed 2x with PBS and fresh 10% serum DMEM was added. One day later, puromycin was 
added to wells and cells were selected for 10 days.  
2.2.10 IL-22 treatment 
A549 and 201T cells were plated at 250,000 cells per well in 6-well plates in DMEM containing 
10% serum and allowed to adhere overnight. Plates were then washed with PBS twice and serum 
free DMEM was added. 18 hours later 25ng of IL-22 (eBioscience # 14-8229-63) was added to 
the existing serum-free media for various timepoints (10, 15. 30 and 60 minutes). Cells were 
washed twice with PBS, frozen in liquid nitrogen, lysed with 2x cell lysis buffer plus 
protease/Phosphatase inhibitor Cocktail (Cell Signaling # 9803 and # 5872). 
2.2.11 In vitro JAK inhibiton 
Cells were plated at 250,000 cells per well in 6-well plates in DMEM containing 10% serum and 
allowed to adhere overnight. Plates were then washed with PBS twice and serum free DMEM 
was added. A JAK inhibitor (Millipore #42009918) diluted in DMSO was added to the serum 
free media along with DMSO control for 2 hours. After 2 hours, 10ng of IL-22 (eBioscience # 
14-8229-63) was added to the existing serum-free media plus inhibitor and DMSO control for 15
minutes. Cells were washed twice with PBS, frozen in liquid nitrogen, lysed with 2x cell lysis 
buffer plus protease/Phosphatase inhibitor Cocktail (Cell Signaling # 9803 and # 5872). 
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2.2.12 Immunoblotting 
Protein concentrations were calculated using a BCA Protein Assay Kit (Pierce #23225) and were 
separated using NuPAGE 4-12% Bis-Tris gels (Life Technologies) followed by transfer to PVDF 
membranes. Membranes were blocked for either 2 hours at room temperature or overnight at 4C 
in 5% milk in PBS-tween. Primary antibodies were incubated either overnight at 4C or for 2 
hours at room temperature followed by secondary antibody for 1 hour at room temperature. 
Membranes were incubated in SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific Rockford, IL) for 5 min. and then developed using an x-ray film processer. Primary 
antibodies include; IRS-1 (1:250, Cell Signaling # 2382), pSTAT3 (1: 1,000 Cell Signaling 
#9271), STAT3 (1:1,000 Cell Signaling #9145), pAKT (ser473) (1:250 Cell Signaling # 9271), 
AKT (1-1,000 Cell Signaling # 9272), pGSK-3B (ser9) (1:1,000 Cell Signaling #9336), GSK-3B 
(27C10) (1:1,000 Cell Signaling #9315), PI3K-p85 (1:1,000 Millipore #06-497), IL-22 Receptor 
(1:1,000 Thermo Scientific #PA5-19987). GAPDH (1:10,000 Cell Signaling #2118) and 
Ponceau stain (Sigma #P3504) was used as load control.  
2.2.13  Human Tissue Microarray (TMA) 
A lung adenocarcinoma cohort on tissue microarray was obtained from the University of 
Pittsburgh Cancer Institute (UPCI). The TMA consists of 135 cases. Each case is annotated as 
either KRAS mutant, EGFR mutant, or WT for both EGFR and KRAS. Survival data and known 
prognostic factors (age, tumor stage, mutational status, etc.) were available through the UPCI 
cancer registry. Patient identifiers were removed and the study was therefore considered “not 
human subjects” research (IRB exempt).  
 
 30 
FFPE sections were stained with an IRS-1 antibody (Santa Cruz #sc-720, Dallas, TX). 
Digital images of IHC-stained (with IRS-1 antibody) TMA slides were obtained at 20x 
magnification (0.5 µm per pixel) using a whole slide scanner (ScanScope AT, Aperio) fitted with 
a 20x/0.75 Plan Apo objective lens (Olympus, Center Valley, PA, USA). Images were saved in 
SVS format (Aperio), managed with server software (ImageServer, Aperio), and retrieved with a 
file management web interface (Spectrum, Aperio). 
Under pathologist supervision, the TMA cores were annotated using Aperio’s annotation 
software (ImageScope v12.2, Aperio). For automated image classification, image areas from 
TMAs were annotated that represented five user-defined Image Classes (tumor, stroma, 
inflammation, other, and clear glass) and ranged in morphologic appearance and staining 
intensity of DAB and hematoxylin (counterstain). These image areas were used as input 
parameters for the histologic pattern recognition training software (Genie Training, Aperio) to 
produce a Genie Training Set. The effectiveness of the Genie Training Set was visualized on the 
TMA image test regions (TMA spots) using the image classifier algorithm (Genie Classifier, 
Aperio), which overlaid an image markup pseudo colored for each Image Class. Annotated 
image areas from the TMA were adjusted (adding or removing image areas) for each Image 
Class to improve the classifier accuracy. For example, if the Genie Classifier algorithm over-
classified regions of stroma as tumor, additional stromal annotations were added to the Genie 
Training algorithm to better represent the stromal Image Class. This process of adjusting 
annotations, re-running the Genie Training algorithm, and visually inspecting pseudo colored 
markup images output by Genie Classifier was iteratively repeated until a Genie Training Set 
was developed to classify the TMA slides optimally, as visually validated by a pathologist. The 
optimized Genie Classifier was then run on the TMAs. 
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IHC staining was evaluated within tumor areas only of each TMA spot that had been 
manually annotated, and a separate analysis was performed on areas from each TMA spot that 
had been classified as tumor by the Genie Classifier. The Color Deconvolution algorithm 
(Aperio) was used to isolate individual stains for quantification: the red, green, and blue (RGB) 
OD color vectors were measured for each stain using default software settings for hematoxylin 
and DAB. The average RGB OD values (Hematoxylin: 0.65, 0.704, 0.286; DAB: 0.268, 0.57, 
0.776) were utilized in the Color Deconvolution software to define each stain component in the 
final analysis settings. Staining was quantified by the following metrics: the percentage of tumor 
with IRS-1 staining (% Strong, Medium, and Weak Positivity), and the Score. The H-Score was 
calculated by a simple formula involving the positive percentages. Score = 1.0*(%Weak) + 2.0* 
(%Medium) + 3.0*(%Strong).  
H&E stained sections were obtained from the UPCI and were scored for myeloid and 
lymphocytic cell inflammation. The specimens were scored as follows for each:  absent = 0, 
sparse cellular content = 1, moderate cellular content = 2, heavy cellular infiltration = 3.  
2.2.14  Statistical Analysis  
Statistical Analysis. For human TMA, overall survival (OS) was calculated from the date of 
diagnosis to the date of death or last confirmation of vital status. Associations between overall 
survival and clinical and novel predictors were assessed using the log-rank test and by Cox 
proportional hazards regression.  Recursive partitioning, a tree-based survival analysis method, 
was used to identify an optimal IRS-1 H-score cutpoint in a univariate survival model [Breiman 
et al 1984 book]. Dichotomized IRS-1 and clinical predictors with strong associations with 
survival in our data or in the literature (sex, age, mutational phenotype [K-ras, EGFR, Wild-
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type], TNM stage, smoking status [never/former/current]) were considered for a multivariable 
Cox regression model. Statistical analyses were conducted using SAS/STAT software, version 
9.4 (SAS Institute, Inc., Cary, NC) and R version 3.1.3 (R Foundation for Statistical Computing, 
Vienna, Austria) including the rpart package.  
Kaplan-Meier survival curves were generated using Prism Software. For all other studies, 
both in vitro and in vivo, either Student’s t-tests (two-sided, two-sample) or one-way ANOVA 
(with Tukey Post-Test) were used, as appropriate. Data expressed as mean ± SEM. A P value < 
0.05 was considered significant.  
2.3 RESULTS 
2.3.1 K-RAS mutant, IRS-1low lung adenocarcinomas display reduced patient survival  
To evaluate the significance of IRS-1 protein content on L-ADCA patient outcomes, we stained 
and analyzed a human tissue microarray (TMA) consisting of 135 primary tumor specimens that 
had been annotated for KRAS and EGFR mutation status, and for which detailed outcomes data 
was available. Immunohistochemistry for IRS-1 was performed and the staining was quantified 
using an Aperio Genie system. Tumor, stromal and inflammatory compartments were scored 
independently. H-scores were generated by assessing the IRS-1 staining intensity specifically 
within the tumor compartment. Examples of H&E-stained, IRS-1-stained and Genie overlay of 
IRS-1high and IRS-1low cases are shown in Figure 1A-C. The analysis was performed on 124 
specimens, as inadequate tissue precluded an assessment of IRS-1 staining on the remaining 11 
cases.  
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As a continuous variable, IRS-1 expression did not predict overall survival (OS) (hazard 
ratio=0.99, 95% CI 0.98-1.00, p=0.14). Threshold effects were explored using recursive 
partitioning, identifying an H-score cutpoint of 130 (Figure 1D, log-rank test p-value = 0.01).  
Evaluated in subgroups by mutational status, the prognostic signal for dichotomized IRS-1 
appeared to be driven by tumors with KRAS mutations (Figure 1E).  In these patients, median OS 
was 50 months for IRS-1low (95% confidence interval 30-84 months) and 131 months for IRS-
1high (71-131 months). EGFR mutant and Wild-type subgroups did not demonstrate IRS-1 as a 
strong prognostic factor (Figure 1F-G). The effect of IRS-1 persisted in a multivariable model 
including established prognostic factors: controlling for clinical stage (as a continuous variable 
with Stages 1A-4 all represented, though 63% were stage 1) and smoking status (never, former, 
current smoker), the hazard ratio for dichotomized IRS-1 was 2.4 (95% CI 1.4-4.3): patients with 
IRS-1low tumors had a hazard of death 140% greater than those with IRS1high (Wald test p-
value=0.002). Thus, we have concluded that IRS-1 deficiency confers decreased survival in L-
ADCA patients, particularly for those with KRAS mutant tumors. 
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Figure 3. IRS-1 predicts patient survival in lung adenocarcinoma: (A-B) Representative images 
of IRS-1low ((H-score < 130) and IRS-1high (H-score >130) human lung adenocarcinoma TMA 
sections stained for (A) H&E and (B) IRS-1. (C) Example of tumor compartment specific 
quantification of IRS-1 staining using Aperio Genie. (D-G) Kaplan-Meier estimates of overall 
survival for the (D) entire lung adenocarcinoma cohort (N=124, P=0.01, (E) KRAS mutant cases 
(N=62, P=0.006), (F) EGFR mutant cases (N=29, P=NS), and (G) Non-KRAS, non-EGFR 
mutant cases (N=33, P=NS). All P values determined from log-rank tests.  
2.3.2 K-ras/Irs-1fl/fl mice display increased tumor burden and decreased survival 
To further interrogate the phenotype identified in the human TMA study, we generated Lox-
Stop-Lox (LSL) K-ras/Irs-1+/+ and LSL-K-ras/Irs-1fl/fl mice on a pure 129.SvJ genetic 
background. Mice were treated with Adenoviral Cre recombinase (AdCre) at 8 weeks of age to 
activate mutant Kras expression and studied over a time course ranging from 4- to 20-weeks 
post-AdCre. Similar to the findings in human L-ADCA, Kaplan-Meier survival curve analysis 
demonstrated a statistically significant reduction in survival for LSL-Kras/Irs-1fl/fl mice when 
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compared to the Irs-1 sufficient group (p<0.0001) (Figure 2A). LSL-Kras/Irs-1fl/fl mice displayed 
a median survival of 13.57 weeks, as compared to a median survival of 19.86 weeks (mice 
censored at 20 weeks) in the LSL-K-ras/Irs-1+/+ control group. Additionally, tumor burden was 
quantified at 4-, 8-, and 12-weeks post-AdCre (Figure 2B-D). Statistically significant increases 
in tumor burden were observed in IRS-1 deficient mice at the 8- and 12-week time points, 
representing a doubling and tripling of the tumor burden identified in control mice and the two 
time points, respectively. 
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Figure 4. Increased tumor burden and mortality in LSL-Kras/Irs-1fl/fl mice: Kaplan-Meier 
estimates of overall survival for AdCre-treated LSL-Kras-Irs-1+/+ (N=40) and LSL-Kras/Irs-1fl/fl 
(N=45) mice. P<0.0001, log-rank test. (B) Tumor area percent (% of lung tissue occupied by 
tumor) for LSL-Kras-Irs-1+/+ and LSL-Kras/Irs-1fl/fl mice at 4-, 8-, and 12-weeks post-AdCre. 
N=6 each group. Bars ± SEM. *P<0.05. (C) Representative H&E stained images for LSL-Kras-
Irs-1+/+ and LSL-Kras/Irs-1fl/fl mice 4-, 8-, and 12-weeks post-AdCre. (D) Representative Irs-1 
stained images for LSL-Kras-Irs-1+/+ and LSL-Kras/Irs-1fl/fl mice at 12-weeks post-AdCre.  
2.3.3 Increased neutrophilic inflammation in LSL-Kras/Irs-1fl/fl mice  
Surprisingly, the most striking initial phenotypic difference apparent in the LSL-K-ras/Irs-1fl/fl 
mice was a dramatic increase in inflammatory cell content in the bronchial alveolar lavage 
(BAL) fluid (Figure 3A-B). Further investigation revealed robust increases in macrophage, and 
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especially in neutrophil content (Figure 3A-B). At 12 weeks, neutrophils were ~5 fold higher in 
LSL-K-ras/Irs-1fl/fl mice and Ly6G staining revealed the presence of tumor-associated 
neutrophils (Figure 3C). RNA was isolated from LSL-Kras and LSL-K-ras/Irs-1fl/fl frozen lung 
tissue and subject to qPCR to assess for differential expression of CC and CXC chemokines 
known to recruit myeloid lineage cells to the TME. LSL-Kras/Irs-1fl/fl mice displayed significant 
increases in most of these chemokines when compared to LSL-Kras mice (Figure 3D). 
Specifically, we identified statistically significant increases in CCL-2, -3, -4, and CXCL-1, -2, 
and -5, consistent with the BAL cellular content data.  
To verify a tumor-promoting role for tumor associated neutrophils, we treated both 
cohorts of mice with an Ly6G antibody, which reduced both tumor associated neutrophilic 
inflammation and tumor growth (not shown), consistent with prior reports.  
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Figure 5. Increased tumor-associated inflammation in LSL-Kras/Irs-1fl/fl mice: (A) 
Bronchoalveolar lavage (BAL) fluid content of neutrophils, macrophages, and lymphocytes from 
LSL-Kras-Irs-1+/+ and LSL-Kras/Irs-1fl/fl mice at 4-, 8-, and 12-weeks post-AdCre. N=6 each 
group. Bars ± SEM. *P<0.05. (B) Representative Hema-3 stained cytospins performed on BAL 
fluid from LSL-Kras-Irs-1+/+ and LSL-Kras/Irs-1fl/fl mice at 12-weeks post-AdCre. (C) 
Representative anti-Ly6G (neutrophil marker) stained sections from LSL-Kras-Irs-1+/+ and LSL-
Kras/Irs-1fl/fl mice at 12-weeks post-AdCre. (D) Real-time PCR values for the listed genes from 
LSL-Kras-Irs-1+/+ and LSL-Kras/Irs-1fl/fl mice at 8-weeks post-AdCre. N=4 each group. Results 
expressed as fold change from LSL-Kras-Irs-1+/+ values  ± SEM. *P<0.05. 
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2.3.4 L-22 is required for increased chemokine response in IRS-1 deficient cancer cells 
In order to further evaluate the differences in chemokine production observed between Irs-1 
deficient and Irs-1 sufficient mice, we generated IRS-1 deficient A549 (KRAS mutant) lung 
adenocarcinoma cells using shRNA approaches. We were not able to observe an increase in 
cytokine or chemokine production in a microarray study of IRS-1 silenced A549 cells under 
standard serum conditions (Table 1). We then reasoned that a factor present in the TME, but not 
present in cancer cells in tissue culture might be responsible for the in vivo observations in LSL-
Kras/Irs-1fl/fl mice. Initially, we confirmed that Th17 cytokines were present in the LSL-Kras 
mouse model, as has been reported [145], by using flow cytometry to document the presence of 
Th17 cells (produce both IL-17 and IL-22) within the TME (not shown). Additionally, we 
confirmed the presence of Th17 cells in the TME of human L-ADCA specimens, also using flow 
cytometry (not shown). Next, we tested the ability of IL-6, IL-17A and IL-22 to induce greater 
CC and CXC chemokine expression from IRS-1 deficient cancer cells in vitro, as they are all 
known to do so under the appropriate conditions. A549 cells permanently silenced for IRS-1 
(shIRS-1) and vector control (shCon) A549 cells were stimulated with the above cytokines and 
qPCR was performed to assess for differences in cytokine and chemokine production (Figure 
4A). Aside from an IL-6 response in the no stimulation and IL-6 treatment groups, only IL-22 
generated an increase in cytokine and chemokine production in IRS-1-deficient cells. Since 
survival differences in human L-ADCA were limited to the KRAS mutant group, we repeated 
these experiments in 201T L-ADCA cells, which harbor WT KRAS alleles. TGFB was induced 
by IL-6, IL17A and IL-22 treatments, but other cytokines and chemokines were not upregulated 
by IRS-1 deficiency in the absence of KRAS mutation (Figure 4B).   
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Table 1: IRS-1-deficient A549 cells do not display chemokine production under unstimulated 
conditions. Microarry analysis was performed on siSCR and siIRS-1 A549 cells cultured under 
normal conditions. 
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Figure 6. IRS-1 deficiency enhances IL-22 signaling: (A-B) Real-time PCR values for the listed 
genes from lentiviral shControl and shIRS-1 transfected (A) A549 and (B) 201T cells treated 
with either IL-6, IL-17A, or IL-22. Results expressed as fold changed in gene expression from 
shControl values ± SEM. *P<0.05.  (C) Western blot for control and IRS-1 silenced A549 cells 
(KRAS mutant) both with and without IL-22 stimulation probed for IRS-1, STAT3, and pSTAT3. 
(D) Band densitometry comparing pSTAT3 content from lane 3 vs. lane 4 from (C) above. 
Quantification performed on an N=4 blots. Bars ± SEM. *P<0.05. (E) Western blot for control 
and IRS-1 silenced 201T cells (KRAS WT) both with and without IL-22 stimulation probed for 
IRS-1, STAT3, and pSTAT3.  (F) Band densitometry comparing pSTAT3 content from lane 3 
vs. lane 4 from (E) above. Quantification performed on an N=4 blots. Bars ± SEM.  (G) Real-
time PCR values for listed genes from control and IRS-1 silenced A549 cells pre-treated with a 
JAK inhibitor (Calbiochem #420099) and stimulated with IL-22. Results expressed as fold 
change from control values. Bars ± SEM. (H) Western blot probed for STAT3 and pSTAT3 from 
A549 cells treated with a JAK inhibitor over the indicated concentrations and stimulated with IL-
22.  
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2.3.5 IL-22 stimulation causes exaggerated pSTAT3 production in KRAS mutant, IRS-1 
silenced cells  
IL-22 is a known inducer of JAK/STAT signaling. To investigate the impact of IRS-1 deficiency 
on IL-22 induced JAK/STAT signaling, we treated shIRS-1 and shCon A549 and 201T cells 
with IL-22, both with and without the presence of a JAK inhibitor. As expected, IL-22 
stimulation increased the production of pSTAT3 when compared to non-IL-22 stimulated control 
cells, for all conditions. Predictably, the addition of a synthetic JAK inhibitor (Calbiochem 
#420099) abrogated pSTAT3 production and cytokine/chemokine induction under all conditions. 
Notably, IRS-1 silenced A549 cells (KRAS mutant) displayed an even greater increase in 
pSTAT3 production upon IL-22 stimulation than did IRS-1 sufficient A549 cells (Figure 4C and 
E). In contrast, IL-22 induced pSTAT3 production was similar in magnitude between IRS-1 
silenced and vector control 201T cells (KRAS WT).  To demonstrate that this mechanism was 
operative in vivo, FFPE sections from LSL-Kras/Irs-1+/+ and LSL-K-ras/Irs-1fl/fl mice were 
subjected to IHC for pSTAT3 (Figure 5A). Tabulation of the slides confirmed increased pSTAT3 
production in LSL-K-ras/Irs-1fl/fl mice (Figure 5B), when compared to controls, thereby 
validating the in vitro findings with respect to pSTAT3.  
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Figure 7. Increased IL-22RA1 content in IRS-1 silenced cells: (A) Representative images for 
pSTAT3 stained sections from LSL-Kras-Irs-1+/+ and LSL-Kras/Irs-1fl/fl mice at 12-weeks post-
AdCre. (B) Quantification of staining in (A) from N=6 in each group. Bars ± SEM. *P<0.05. (C) 
Representative images for IL22RA1 stained sections from LSL-Kras-Irs-1+/+ and LSL-Kras/Irs-
1fl/fl mice at 12-weeks post-AdCre. (D) Quantification of staining in (C) from N=5 in each group. 
Bars ± SEM. *P<0.05. (E) Control and IRS-1 silenced A549 cells pre-treated with 
cycloheximide prior to IL-22 stimulation. Western blot probed for IL22RA1 was performed on 
membrane fraction. (F) Representative Western blots for the indicated proteins from control and 
IRS-1 silenced A549 and 201T cells. (G) Illustrative diagram depicting the proposed mechanism 
by which IRS-1 deficiency results in exaggerated pSTAT3 production in response to IL22. The 
p85 subunit of PI3K, typically located both within the cytosol and at the cell membrane, is 
preferentially redistributed to the cellular membrane in the absence of IRS-1. In the presence of 
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mutant KRAS, increased bioavailability of p85 results in increased pAkt, and subsequently 
pGSK-3B production. pGSK-3B is known to prolong IL22RA1 half-life via protective 
phosphorylation of its cytoplasmic tail. Increased IL22RA1 half-life results in enhanced pSTAT3 
production in response to IL22 stimulation.  
2.3.6 IRS-1 deficiency prolongs IL-22RA1 half-life via pGSK-3B production 
The increased production of pSTAT3 by IRS-1 deficient cancer cells as compared to IRS-1 
sufficient cancer cells was observed while using an equivalent concentration of IL-22. This 
suggests that the production of pSTAT3 induced by each molecule of IL-22 is greater for IRS-1 
silenced cells compared to controls. The most logical mechanism to explain these observations 
would be a prolongation of the IL-22R half-life in IRS-1 deficient cells. IHC for IL-22RA1 was 
performed on FFPE sections from LSL-K-ras/Irs-1fl/fl mice and appropriate controls. Similar to 
the findings with respect to pSTAT3, LSL-K-ras/Irs-1fl/fl tumor displayed greater than twice the 
IL-22RA1 staining when compared to LSL-K-ras/Irs-1+/+ controls (Figure 5D). To demonstrate 
this more clearly, IRS-1 silenced and vector control A549 cells were treated with cycloheximide 
to inhibit all protein synthesis prior to IL-22 stimulation and subsequent tracking of IL-22RA1 
cycling. The control cells show the natural life cycle of the IL-22RA1 following IL-22 
stimulation. IL-22RA1 signal is gradually lost from the membrane as it is internalized following 
activation, tagged for degradation, and eventually completely absent in the membrane fraction 
(Figure 5E). Since the cells have been treated with cycloheximide, they are incapable of 
repopulating the cell surface with new receptor. In contrast, by the conclusion of the experiment 
in IRS-1 deficient cells, the IL-22RA1 membrane content has been restored, as the receptor has 
been recycled to the membrane, never having been degraded.  
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Recently, pGSK-3B has been shown to phosphorylate the cytoplasmic tail of IL-22RA1, 
which inhibits the ability of ubiquitinases to tag the receptor for degradation [146]. This results 
in a prolongation of IL-22RA1 half-life. Since IRS-1 is a homeostatic binding partner of the p85 
subunit of phospho-inositol 3-kinase (PI3K), and well known to impact PI3K signaling, we 
investigated the impact of IRS-1 deficiency on pAKT and pGSK-3B production in KRAS mutant 
and KRAS WT cells. IRS-1 silencing had little effect on pAKT and pGSK-3B production in 
KRAS WT 201T cells (Figure 5F). However, IRS-1 deficiency in the presence of mutant KRAS 
actually increased both pAKT and pGSK-3B (Figure 5F). Alteration in the sub-cellular location 
of the PI3K machinery is the most likely explanation for this counter-intuitive finding. IRS-1 is a 
signaling adaptor protein, and is therefore able to interact with p85 within the cytosol, following 
phosphorylation by a cell surface receptor. This is in contrast to traditional receptor tyrosine 
kinases that interact with p85 near the inner leaflet of the cellular membrane, where lipid 
substrates are abundant. In the absence of IRS-1, the subcellular location of p85 relocates 
predominantly to the cell membrane, regardless of whether or not mutant K-RAS is present 
(Figure 5F). Similar observations were previously made in adipocytes [147]. Taken together, 
these data suggest that pAKT and pGSK-3B production is increased when p85 is located nearest 
to the phospho-inositols, if a continuous signaling mutated protein is present.  
2.3.7 JAK inhibition reduces inflammation and tumor burden in LSL-K-ras/Irs-1fl/fl 
mice 
Although the increased tumor-associated inflammation and tumor burden identified in LSL-K-
ras/Irs-1fl/fl mice was the result of a multi-step process, all of these steps culminated in 
JAK/STAT activation. Therefore, we administered a JAK antagonist, AZD 1480, to both LSL-K-
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ras/Irs-1+/+ and LSL-K-ras/Irs-1fl/fl mice in attempts to identify a novel therapeutic strategy for 
the K-ras mutant, IRS-1 low tumor subtype.  Mice received either AZD 1480 or vehicle control 
via oral gavage 6 days per week for 3 weeks, starting 8-weeks post-AdCre. Analysis of the 
BALF inflammatory cell content revealed that LSL-K-ras/Irs-1fl/fl mice possessed substantially 
reduced inflammation that was similar in magnitude to that observed in LSL-K-ras/Irs-1+/+ mice 
(Figure 6D and F). AZD 1480 significantly reduced the tumor burden in both groups of mice, 
where the tumor burden was reduced to 5.8% in the LSL-K-ras/Irs-1+/+ mice and 3.8% in the 
LSL-K-ras/Irs-1fl/fl mice (Figure 6 A-C). Mechanistically, JAK inhibition reduced CC and CXC 
chemokine expression, as expected (Figure 6G and H). These results provide evidence that JAK 
inhibition is capable of reducing tumor burden in K-ras mutant mice, and additionally capable of 
abrogating the enhanced tumor-promoting inflammation afforded by IRS-1 deficiency. 
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Figure 8. JAK inhibition reduces tumor burden and inflammation in LSL-Kras/Irs-1fl/fl mice: (A) 
Representative H&E stained sections from LSL-Kras-Irs-1+/+ and LSL-Kras/Irs-1fl/fl mice treated 
with AZD1480 (JAK inhibitor) or vehicle control for a total of 6-weeks beginning at 8-weeks 
post-AdCre. (B-C) Tumor area percent (% of lung occupied by tumor) for (B) LSL-Kras-Irs-1+/+ 
and (C) LSL-Kras/Irs-1fl/fl mice treated with either AZD1480 or vehicle control, as above. N>4 
 48 
each group. Bars ± SEM. *P<0.05. (D) Representative images of, and (E-F) quantification of 
Hema-3 stained cytospins of BAL fluid from LSL-Kras-Irs-1+/+ and LSL-Kras/Irs-1fl/fl mice on 
therapy with either AZD1480 or vehicle control. (G-H) Real-time PCR values for the listed 
genes from (G) LSL-Kras-Irs-1+/+ and (H) LSL-Kras/Irs-1fl/fl mice treated with either AZD1480 
or vehicle control, as above. Results are expressed as fold change from vehicle control ± SEM. 
N=3 each group. *P<0.05. 
2.3.8 K-RAS mutant, IRS-1low human lung adenocarcinomas contain increased myeloid 
cell inflammation  
To validate the mechanistic findings in LSL-K-ras/Irs-1fl/fl mice, we re-analyzed our human lung 
adenocarcinoma TMA for immune cell content. Specifically, we scored all K-RAS mutant cases 
in our TMA for myeloid cell infiltration and lymphocyte infiltration (both on a semi-quantitative 
score from 0-3, where absent = 0, mild = 1, moderate = 2, and heavy = 3). These scores were 
also combined to give a total immune cell content score. K-RAS mutant, IRS-1low cancers 
possessed ~30% greater content of inflammatory cells, and ~40% increased myeloid cell 
infiltration, but no significant difference in lymphoid inflammation was identified, consistent 
with the findings in the K-ras mouse model (Supplementary Figure 1).  
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Figure 9. KRAS-mutant, IRS-lLow human lung adenocarcinomas have increased myeloid cell 
infiltration: (A) Representative H&E images from myeloid and lymphocyte high and low cases. 
(B) Quantification of total, myeloid and lymphoid inflammation between IRS-1 High and IRS-
1Low patients. 
2.4 DISCUSSION 
It has become clear that inflammatory responses can promote tumor initiation and progression. 
Numerous studies have uncovered elaborate mechanisms by which aberrant immune cell 
function promotes tumorigenesis. Yet, the mechanisms by which these immune cells have been 
recruited and by which their function has been polarized, remain poorly understood. Here, we 
show that deficiency of a homeostatic protein, IRS-1, skews cancer cell signaling towards a pro-
inflammatory phenotype. 
We began this study of IRS-1 in lung cancer by identifying that IRS-1 deficient lung 
adenocarcinomas displayed reduced survival, but that this phenotype was restricted to the KRAS 
mutant L-ADCA subtype. Controlled experiments in mice reproduced the phenotype observed in 
humans and uncovered a pro-inflammatory phenotype highlighted by enhanced pSTAT3 
production, excessive CC and CXC chemokine expression, and consequential increases in 
inflammatory cell content. We suspect that most, but not all, of the differences in tumor burden 
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were the result of increased tumor-promoting inflammation, and were able to diminish tumor 
burden using a neutrophil depleting antibody, as has been reported several times previously. 
Moreover, antagonism of the JAK/STAT pathway abrogated increases in inflammation and 
tumor burden afforded by IRS-1 deletion. Mechanistically, IRS-1 deficient cells display an 
altered sub-cellular distribution of the PI3K machinery, favoring a plasma membrane location. 
Under certain circumstances, such as the presence of mutant KRAS, abundant PI3K within close 
proximity to its lipid substrates can enhance PI3K pathway activity, as observed here. In this 
case, increased pGSK-3B production increased the half-life of IL-22RA1, ultimately causing 
enhanced pSTAT3 production, CXC chemokine expression, and increased pro-tumor 
inflammatory cell infiltration.  
The importance of the Th17 cytokines IL-17 and IL-22 in solid tumor malignancies has 
been highlighted by several recent publications. Though we were unable to identify a role for IL-
17A specifically in the context of IRS-1 deficiency, IL-17A-deficient mice were recently shown 
to display reduced tumor burden and tumor-associated inflammation in the LSL-Kras model 
employed here [145]. Notably, IL-22 has recently been shown to play dual roles in cancer. Early 
in the process of tumorigenesis, IL-22 is essential for epithelial cell repair, and actually retards 
tumor formation. In contrast, in established lesions in pro-inflammatory colon cancer models, IL-
22 drives myeloid cell infiltration and tumor burden via JAK/STAT mediated amplification of 
CC and CXC chemokine production [148], similar to our findings. Whether reduced IRS-1 
protein content is encountered in other malignancies, and if this impacts IL-22 signaling, is an 
active area of study in our laboratory.  
This is the first definitive report of a pro-host role for IRS-1 in any human cancer type 
and is paradigm shifting in nature.  Traditionally, IRS-1 is considered a positive effector of 
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growth factor and presumed to promote tumor growth via PI3K activation, which is likely the 
case in certain malignancies. Several IHC based studies have correlated IRS-1 staining with poor 
outcomes, including myosarcoma, leiomyosarcoma, lipsarcoma, rhabdomyosarcoma, and 
hepatocellular carcinoma [149]. The only prior study of IRS-1 in human lung cancer reported 
that 46% of NSCLC cases had diminished IRS-1 content by IHC, though outcomes data were not 
available [150]. Notably, we denoted 38% of L-ADCA on the TMA as being IRS-1 low, 
consistent with the prior study. Taken together, these studies strongly suggest that approximately 
40% of L-ADCA tumors display reduced IRS-1 content at the protein level. Specifically within 
the KRAS mutant group, 37% of cases were defined as IRS-1 low, such that ~10% of all L-
ADCA is comprised of this unique subtype. Furthermore, these findings may shed light as to 
why initial clinical trials employing IGF-1R antagonists have not produced positive results. IGF-
1R inhibition would be expected to reduce the pTyr-IRS-1 cellular content, which would reduce 
IRS-1:p85 interaction as only pTyr-IRS-1 binds to p85. Thus, IGF-1R inhibition may generate a 
relatively deficient IRS-1 state, which in the presence of mutant KRAS, may produce untoward 
effects.   
One potential shortcoming of the current study is that we have not identified the 
mechanism by which IRS-1 protein content is reduced in human L-ADCA. It unlikely to be the 
result of a mutation, as IRS-1 mutations were not reported in the lung adenocarcinoma TCGA 
dataset. There is one prominent polymorphism known to occur in IRS-1 that impacts p85 binding 
(G972R), though it has not been described to impact protein levels. The remaining mechanistic 
possibilities include epigenetic silencing, post-transcriptional silencing, or post-translational 
degradation. We previously identified a significant correlation between neutrophil elastase 
staining and reduced IRS-1 staining on serial sections of 38 human lung adenocarcinomas using 
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IHC. However, we have not directly identified the mechanism by which IRS-1 protein content is 
reduced in this context in human disease.  
The results reported here highlight a novel concept with respect to pathway signaling in 
cancer cells. Whereas the focus of aberrant pathway signaling has logically centered upon 
hyperactive mutant proteins (K-RAS, PIK3CA, B-RAF, etc.), this report clearly demonstrates 
that signaling intermediaries can drastically impact cell behavior when their content is reduced. 
Signaling intermediates are numerous, and mutated versions of many of these proteins are not 
frequently encountered. However, relative deficiencies of promiscuous signaling proteins, such 
as IRS-1, can impact pathway output in a manner that is difficult to predict. Furthermore, 
reductions in pathway intermediates should be considered in the context of mutant oncogenes, as 
the impact on cell behavior can be impacted by unique combinations.  
KRAS mutant, IRS-1low lung adenocarcinomas represent a unique subtype in which 
JAK/STAT activation is excessive, and drives tumor-promoting inflammation. Since the 
constellation of events instigated by IRS-1 deficiency culminates in pSTAT3 production, we 
used a JAK inhibitor to show that this tumor subtype is particularly susceptible to this 
therapeutic strategy.  Since KRAS mutant, IRS-1low lung adenocarcinomas represent 10% of all 
lung adenocarcinomas, JAK inhibition may represent a viable therapeutic option, especially 
when considering the intractable nature of KRAS mutant cancers. Lastly, the ability of JAK 
inhibition to reduce myeloid cell infiltration and tumor burden in LSL-Kras mice suggests that 
this may be a viable strategy to address myeloid derived suppressor cell (MDSC) content in solid 
tumors, a strategy for which there are no approved therapies.
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3.0  IRS-1 AND CELLULAR PROLIFERATION 
The work in Chapter 2 was preceded by studies involving the role of IRS-1 in cellular 
proliferation. A paper entitled, Neutrophil elastase-mediated degradation of IRS-1 accelerates 
lung tumor growth [88] (Appendix B) describes a role for IRS-1 in lung adenocarcinoma in 
which IRS-1 is degraded by Neutrophil elastase and the loss of this protein induces cellular 
proliferation. Overall, this work showed that Neutrophil elastase increases tumor burden and 
decreases survival in mice, neutrophil elastase degrades IRS-1 within the cell inducing 
proliferation through activation of more potent receptors and also that human lung 
adenocarcinoma cases display an inverse correlation between neutrophil elastase and IRS-1 
presence. 
My specific contributions to this paper involved performing experiments for the in vitro 
mechanism of this phenotype.  I performed experiments in which neutrophil elastase-sufficient 
and –deficient mouse neutrophils were co-cultured with LSL-K-ras tumor-derived cell lines and 
then thymidine incorporation assays were used to evaluate cellular proliferation. Exposure to 
neutrophil elastase increased cellular proliferation (Appendix B, Figure 11 a). I then performed 
experiments in which LSL-K-ras cell lines and human lung adenocarcinoma cell lines (A549 and 
201T) were exposed to different concentrations of neutrophil elastase. Thymidine incorporation 
and cell count assays as well as western blots were then performed. Exposure to 40nM and 80nM 
neutrophil elastase increased cellular proliferation (Appendix B, Figure 11 b-e). Western blots 
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displayed increased pAKT in three different cell lines at increasing concentrations of neutrophil 
elastase (Appendix B, Figure 11g). MAPK, however, was not increased with exposure to 
neutrophil elastase (Appendix B, Figure 11 f). A proliferation assay was performed on A549 
cells pre-treated with a PI3K inhibitor (LY294002) and a MAPK inhibitor (U0126) (Appendix B, 
Figure 11 f). The results of this displayed the reliance on AKT signaling for proliferation due to 
neutrophil exposure, as the PI3K inhibitor reduced proliferation back to baseline. I also 
performed a proliferation assay of neutrophil elastase-treated A549 cells that were also pre-
treated with Dynasore, an inhibitor of endosome formation (Appendix B, Figure11 j). Cells 
treated with Dynasore did not proliferate upon neutrophil elastase treatment, indicating that 
neutrophil elastase must enter the cell in an endosomal compartment in order to have an effect.  
The hypothesis evolved from here into an investigation of the PDGF receptor. I 
performed co-immunoprecipitation experiments involving the p85 subunit of PI3K and the 
PDGF receptor (Appendix B, Figure 12 c, d). Results indicated that p85 is in fact bound to the 
PDGF receptor more readily with exposure to neutrophil elastase. I then performed a PDGF 
receptor knock-down experiment in A549 cells and evaluated proliferation using a thymidine 
uptake assay (Appendix B, Figure 12 e, f). Silencing of the PDGF receptor reduced neutrophil 
elastase-induced proliferation significantly.  
We then investigated the role neutrophil elastase had on Insulin Receptor Substrate-1. I 
performed an experiment in which recombinant IRS-1 protein was mixed with neutrophil 
elastase in a test tube and then run on a gel and probed for IRS-1 (Appendix B, Figure 13 a). 
IRS-1 was degraded with increasing concentrations of neutrophil elastase. I then treated A549 
cells with neutrophil elastase and ran the whole lysate on a gel and probed for IRS-1 (Appendix 
B, Figure b). IRS-1 was also degraded in vitro with increasing concentrations of neutrophil 
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elastase. I then performed a proliferation assay using siRNA to silence IRS-1 in A549 cells 
where it was found that loss of IRS-1 increased cellular proliferation (Appendix B, 13 c). I also 
overexpressed IRS-1 in A549 cells and found that overexpression greatly reduces proliferation 
(Appendix B, 13 d).  
Another paper I was involved in entitled, Neutrophil Elastase Promotes Myofibroblast 
Differentiation in Lung Fibrosis [151], describes a role for IRS-1 in fibroblast proliferation. 
Briefly, this paper shows that neutrophil elastase-deficient mice have reduced lung fibrosis from 
asbestos exposure and reduced myofibroblast levels. Neutrophil elastase was found to increase 
fibroblast proliferation and increase myofibroblast differentiation. For this paper, I performed 
experiments in which proliferation was evaluated for both neutrophil elastase exposure and 
knock-down of IRS-1 (Appendix C, Figure A-D and I-J). These experiments indicated that 
neutrophil elastase induces proliferation in fibroblast cells and that loss of IRS-1 specifically 
produces this effect.  
These two papers led to the independent evaluation of IRS-1 in lung adenocarcinoma 
(Chapter 2). We were interested in further elucidating the mechanism responsible for increased 
proliferation upon IRS-1 loss. To our surprise, IRS-1 loss did more than just induce proliferation; 
it also activated a signaling cascade culminating in increased chemokine production and thus 
increased immune cell recruitment to the tumor microenvironment. Taking a broader and also a 
more controlled look at IRS-1 allowed us to identify a population of people who currently do not 
have any targeted therapies available to them (KRAS-mutant, IRS-1Low L-ADCA) and 
hypothesize that they may benefit from JAK inhibitor therapy based on a mouse pre-clinical trial. 
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4.0  SUMMARY AND FUTURE DIRECTIONS 
The overarching goal of this work was to investigate novel roles for IRS-1 in the lung, including 
its role as a key mediator of homeostasis in cancer cells and fibroblasts, as well as its role in 
regulating immune cell recruitment to the tumor microenvironment. The studies described in 
chapters two and three, and appendix B and C reveal a counter-intuitive role for IRS-1 in which 
its loss induces cellular proliferation. Chapter three and appendix B describe a novel role for 
IRS-1 in which an intracellular adaptor molecule within a tumor cell regulates immune cell 
content in the tumor microenvironment as a whole. These studies have identified a population of 
patients within the lung adenocarcinoma subtype and provide possible therapeutic targets for this 
deadly disease.  
Chapter three and appendix B investigate the loss of IRS-1 in cancer cells, which occurs 
through degradation by Neutrophil Elastase (NE) secreted from neutrophils in the tumor 
microenvironment. The goal of this study was to determine if NE affected tumor progression. A 
model combining the Kras mouse model of lung adenocarcinoma and an NE-deficient mouse 
displayed increased survival and decreased tumor burden in Kras-NE-deficient mice. It was also 
noted that Kras-NE-deficient mice had increased pAkt production. IRS-1 is a key player in AKT 
signaling and was reduced in Kras-NE-sufficient mice. In vitro experiments demonstrated that 
NE directly degrades IRS-1 and that once IRS-1 is lost, p85 can bind more potent growth factor 
receptors, thus increasing cellular proliferation.  
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Chapter two represents the follow-up to this study, in which IRS-1 loss was 
independently evaluated without other confounding factors contributed by NE.  The goal of this 
study was to evaluate the role of IRS-1 in cellular proliferation. A study using a human lung 
adenocarcinoma tissue microarray stained for IRS-1 revealed significant survival differences 
between IRS-1High and IRS-1Low patients in the KRAS subtype. Kras and Kras, Irs-1-deficient 
mice were employed to evaluate this phenotype further. Kras, Irs-1-deficient mice displayed 
increased mortality and tumor burden. A surprising finding in the study was an increase in 
immune cells in the BAL fluid in Kras, Irs-1-deficient mice. Further interrogation revealed that 
loss of IRS-1 increased the release of chemokines by tumor cells through increased JAK/STAT 
signaling in the setting of IL-22 stimulation. The link between IRS-1 loss and increased 
JAK/STAT signaling is through an increase in pAKT as was described in chapter three and 
appendix B. This increase in pAKT causes downstream phosphorylation of pGSK3β, which in 
turn stabilizes the IL-22 receptor allowing for elevated JAK/STAT signaling. This work also 
demonstrated that JAK inhibition reduced tumor burden, chemokine production and 
inflammation in our mouse model.  
Future directions for this study could be extended to clinical trials in lung 
adenocarcinoma patients, with a specific focus on the KRAS mutant subtype. There are several 
JAK inhibitors currently in clinical trial for pancreatic cancer, acute myeloid leukemia, psoriasis 
inflammatory bowel disease and rheumatoid arthritis [103]. Another important consideration 
would be the impact of different KRAS mutations on the signaling we have described. Ihle et al. 
describe KRAS point mutations that have different consequences for downstream signaling as 
well as patient survival [126]. It was shown that KRAS-G12D had increased PI3K and MEK 
signaling but KRAS-G12C and KRAS-G12V had increased Ral signaling [126]. It would be 
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informative to evaluate the specific KRAS mutations present in our TMA cohort and compare 
each to IRS-1 levels and survival outcomes. Understanding which specific KRAS mutation 
affects which signaling pathway would help direct patient care. 
Another interesting follow-up would be to investigate the role of immune checkpoint 
inhibitors in the Kras and Kras, Irs-1-deficient mouse model. Cytotoxic T lymphocytes (CTL) 
are CD8+ T cells that are capable of killing tumor cells. Tumor cells evade this destruction by 
expressing immune checkpoint ligands including programmed death-1 ligand (PD-L1) that 
neutralizes the CTL’s ability to kill by interacting with the programmed death-1 (PD-1) receptor 
[152]. Immune checkpoint inhibitors have recently been developed that aim to block the 
interaction of PD-1 and PD-L1, thus allowing the immune system to recognize and eliminate 
cancer cells. There are currently three PD-1/PD-L1 inhibitors for lung cancer including 
nivolumab, pembrolizumab and MPDL3280A [153]. It would be interesting to evaluate these 
drugs in KRAS mutant lung adenocarcinoma in combination with JAK inhibition.  
IL-22 presents another target for potential therapy. We found that IL-22 in the tumor 
microenvironment activated JAK/STAT signaling through the IL-22 receptor and caused an 
increase in tumor burden and decrease in survival. Blocking either IL-22 or the IL-22 receptor 
may reduce this response. A neutralizing antibody against IL-22 is currently in clinical trial for 
psoriasis and rheumatoid arthritis [154]. Mouse models of IL-22 and IL-22 receptor deficiency 
display many negative side effects, so further investigation using models systems will be 
necessary to properly target these entities without harming the host [154].  
Chapters two and three describe a pro-tumor role for the neutrophil. This concept should 
be taken into consideration with regard to patient treatment following chemotherapy. Many 
patients develop neutropenia following chemotherapy and are given a granulocyte colony-
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stimulating factor (G-CSF) drug such as filgrastim, which stimulates the bone marrow to product 
neutrophils [155]. A study of lung tumor progression in KRAS and KRAS IRS-1-deficient mice 
treated with a G-CSF drug would be an informative study to address the pro-host versus pro-
tumor role of neutrophils.  
Appendix C investigates the role of Neutrophil Elastase in fibroblast proliferation and 
differentiation. In this study C57BL/6 controls and C57BL/6 NE-/- mice were administered 
asbestos intratracheally. The NE-/- mice did not develop fibrosis in response to asbestos and had 
significantly less fibroblast and myofibroblast content in the lungs. In vitro studies revealed that 
NE degrades IRS-1 in fibroblasts as it did in cancer cells as described in appendix B. This loss of 
IRS-1 increased pAKT production and proliferative signaling in the fibroblasts. A synthetic 
small molecule inhibitor of Elastase, ONO-5046, was given to asbestos treated mice and reduced 
the fibrotic phenotype of the C57BL/6 control mice.  
This study provides another non-canonical role for IRS-1 in a non-cancer cell type. 
Fibroblasts are an important component of the tumor microenvironment. There is evidence that 
fibroblasts play a role in cancer progression [156]. A study of lung adenocarcinoma patients 
indicated that carbonic anhydrase IX expression by cancer associated fibroblasts correlated with 
lower patient survival rates [157]. An interesting follow-up study for appendix C would be to 
evaluate fibroblast behavior in a cancer model. The tumor microenvironment consists of many 
different components all contributing to cancer progression in various ways and it will be 
important to gain a better understanding of these interactions. 
In summary, the findings described in this dissertation provide novel roles for IRS-1 as a 
pro-host molecule. The consequences of IRS-1 loss that have been described will hopefully lead 
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to future experiments that will help advance patient care by providing novel targets for 
therapeutic intervention. 
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ABBREVIATIONS 
A1AT, Alpha-1 antitrypsin 
ADCA, Adenocarcinoma 
AdenoCre, Adenoviral cre recombinase 
ALK, Anaplastic lymphoma kinase 
αSMA, alpha smooth muscle actin 
AKT, protein kinas B (PKB) 
BAL, bronchoalveolar lavage 
CG, cathepsin G 
ECM, extracellular matrix 
EGFR, Epidermal growth factor receptor 
FSP-1, fibroblast specific protein-1 
Grb2, Growth factor receptor-bound protein 2 
HCC, Hepatocellular carcinoma 
HER2, Human epidermal growth factor receptor 2 
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IGF-1R, Insulin-like growth factor-1 receptor 
IPF, idiopathic pulmonary fibrosis 
IR, Insulin receptor 
IRS-1, insulin receptor substrate-1 
IRS-2, insulin receptor substrate-2 
JAK, Janus kinase  
KRAS, Kirsten rat sarcoma viral oncogene homolog  
MMP, Matrix metalloproteinase 
MEK/ERK, Extracellular signal regulated kinase  
NE, Neutrophil Elastase 
NSCLC, Non-small cell lung cancer 
PDGF, Platelet derived growth factor 
PDGFR, PDGF-receptor 
PI3K, phosphoinositol-3 kinase 
PIP3, Phosphatidylinositol (3,4,5)-trisphosphate 
PI3KCA, phosphoinositol-3 kinase, catalytic subunit (p110) 
PMN, polymorphonuclear neutrophils 
PMF, primary mouse fibroblasts 
PMSF, phenylmethylsulfonyl fluoride 
PTB, Phosphotyrosine-binding domain 
PTEN, Phosphatase and tensin homolog 
RALA/B, Ras-related protein 
RTK, Receptor tyrosine kinase 
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SH2, Src Homolygy 2 
SCLC, Small cell lung cancer 
STAT, Signal transducer and activator of transcription 
TiO2, titanium dioxide 
TGF-ß, transforming growth factor beta 
VEGFR, vascular endothelial growth factor 
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B.1 SUMMARY 
Lung cancer is the leading cause of cancer death worldwide [158]. Recent data suggest that 
tumor-associated inflammatory cells may modify lung tumor growth and invasiveness [28, 159]. 
To determine the role of neutrophil elastase (NE or Elane) on tumor progression, we utilized the 
LSL-K-ras model of murine lung adenocarcinoma [89] to generate LSL-K-ras/Elane−/− mice. 
Tumor burden was markedly reduced in LSL-K-ras/Elane−/− mice at all time points following 
induction of mutant K-ras expression. Kaplan-Meier life survival analysis demonstrated that 
while 100% of LSL-K-ras/Elane+/+ mice died, none of the mice lacking NE died. NE directly 
induced tumor cell proliferation in both human and mouse lung adenocarcinomas by gaining 
access to an endosomal compartment within tumor cells where it degraded insulin receptor 
substrate-1 (IRS1). Co-immunoprecipitation studies showed that as NE degraded IRS1, there 
was increased interaction between PI3K and the potent mitogen platelet derived growth factor 
receptor (PDGFR) thereby skewing the PI3K axis toward tumor cell proliferation. The inverse 
relationship identified between NE and IRS1 in LSL-K-ras mice was also identified in human 
lung adenocarcinomas, thus translating these findings to human disease. This study identifies 
IRS1 as a key regulator of PI3K within malignant cells. Additionally, this is the first description 
of a secreted proteinase gaining access to a cell beyond its plasma membrane and altering 
intracellular signaling. 
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B.2 RESULTS AND DISCUSSION 
Lung cancer is the leading cause of cancer related deaths worldwide with dismal ~15% five-year 
survival rates despite therapeutic advances over the preceding decades [158]. A better 
understanding of tumor-associated inflammation may identify novel therapeutic targets. 
Neutrophils are known to infiltrate tumors, however, only recently have they been 
thought to modify tumor growth and invasiveness [28, 89, 159-163]. We have previously shown 
that lung cancer cells elaborate CXC chemokines driving neutrophil recruitment. Hence, tumor-
associated neutrophils don't necessarily represent a means of host defense. Indeed, there have 
been reports that neutrophil infiltrates within tumors correlate with poor clinical outcomes [164, 
165]. 
The purpose of this study was to determine if the most potent neutrophil proteinase, NE, 
played a role in tumor progression. NE is a neutrophil-specific serine proteinase with broad 
substrate specificity. Its expression is limited to promyelocyte stages of bone marrow 
development where it is packaged into azurophil granules [166]. The main function of NE is to 
eliminate pathogens within neutrophils [167, 168]. However, upon activation, neutrophils 
translocate NE to the cell surface and secrete small amounts of enzyme from individual granules 
[169]. 
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Figure 10. NE promotes lung tumor growth: (a) Kaplan-Meier Survival curve for AdenoCre 
recipient LSL/K-ras/Elane+/+ and LSL/K-ras/Elane−/− mice; P=0.006, log-rank test. (b) Tumor 
area (%) for both groups at 8, 14, and 20 weeks post-AdenoCre. N=5 mice per group. Bars ± 
SEM. *P<0.01. (c) BALF neutrophil counts for AdenoCre recipient LSL/K-ras/Elane+/+ and 
LSL/K-ras/Elane−/− mice at the 14-week time point. N=5 mice per group. Bars ± SEM. P=NS. 
Representative H&E images at 14 weeks (d, e) and 20 weeks (f) post-AdenoCre. (g) 
Representative images for anti-p40phox (anti-neutrophil) IHC at 14 weeks post-AdenoCre. (h) 
Representative Ki-67 IHC 14 weeks post-AdenoCre. (i) Ki-67 (+) cells per tumor area for N=5 
mice per group at the 14-week time point. Bars ± SEM. *P<0.01. (j) Representative IF images 
and quantification for pAkt and phospho-MEK/ERK from both groups of mice 14 weeks post-
AdenoCre. Bars ± SEM. P<0.01 for pAkt.  
69 
We subjected Lox—Stop—Lox K-rasG12D/Elane−/− (LSL-K-ras/Elane−/−) and control 
(LSL-K-ras/Elane+/+) mice to 5×106 pfu intratracheal adenoviral cre recombinase (AdenoCre) to 
activate mutant K-ras expression4. During the 28 weeks following AdenoCre administration, all 
LSL-K-ras/Elane+/+ but none of the LSL-K-ras/Elane−/− mice died. Survival analysis 
demonstrated a significant (P=0.006) advantage for LSL-K-ras/Elane−/− mice (Fig. 1a). NE-
deficiency is not completely protective, as we have subsequently identified death beyond 30 
weeks in independent studies. Tumor burden was markedly reduced in LSL-K-ras/Elane−/− mice 
at all time points (Fig. 1b,d–f). The differences observed represent a reduction in tumor growth 
and differentiation (less mature lesions), as tumor number was equivalent in the two groups 
(Supplementary Table 1). NE-mediated effects on tumor growth are not model specific, as 
similar reductions in tumor growth were observed in the Lewis Lung carcinoma model using WT 
and Elane−/− mice (Supplementary Fig. 1). 
Immunohistochemical (IHC) analyses and lung lavage cell counts demonstrated 
equivalent neutrophil content and distribution in LSL-K-ras/Elane−/− and LSL-K-ras/Elane+/+ 
mice (Fig. 1c,g), thereby excluding a role for NE in neutrophil trafficking. We also excluded the 
unlikely possibility that LSL-K-ras tumors produced NE using casein zymography (not shown). 
We identified significant reductions in tumor cell proliferation in LSL-K-ras/Elane−/− 
mice (Fig. 1h,i) using Ki-67 IHC. Immunofluorescence (IF) staining demonstrated differential 
activity in the PI3K pathway (pAkt), but specifically not in MEK/ERK (Fig. 1j). Proteinases can 
release growth factors sequestered within extracellular matrix for use by tumors [169, 170] 
which could account for these findings. However, we were unable to detect differences between 
the groups for relevant growth factors (not shown). 
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We examined the possibility that NE could directly induce tumor cell proliferation and 
performed co-culture experiments utilizing WT and Elane−/− PMN to demonstrate an essential 
requirement for NE in PMN-mediated tumor cell proliferation (Fig. 2a). Neutrophils only release 
~2% of their NE content upon activation resulting in modest concentrations (~50 nM) just 
beyond the cell surface [171]. Dose response curves in LSL-K-ras tumor-derived cell lines (Fig. 
2b) confirmed that modest concentrations of NE (40-80 nM) induced cellular proliferation, while 
excessive concentrations caused cell death (Fig. 2b). We reproduced NE-induced proliferation in 
two human lung adenocarcinoma cell lines, A549 (K-ras mutant) and 201T (K-ras WT)(Fig. 2c–
e). The effects of NE required catalytic activity, as inactive NE (heated or synthetic inhibitor) 
failed to induce proliferation (Supplementary Fig. 2). 
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Figure 11. Neutrophil Elastase induces tumor cell proliferation: (a) 3H uptake for LSL–K-ras 
tumor–derived cell lines5 incubated with WT orElane−/− PMNs for 2 h. Results show a 
representative experiment in triplicate. Data represent means ± s.e.m. *P < 0.05 compared to 
control. **P = 0.011, analysis of variance. (b) 3H uptake for LSL–K-ras cells stimulated with 
neutrophil elastase (NE) or vehicle for 60 min. Data from a representative experiment in 
triplicate. Data represent means ± s.e.m. *P < 0.01 compared to NE = 0 (vehicle). (c–e) 3H 
uptake (c) and cell counts (d) for A549 cells and 3H uptake for 201T cells (K-ras WT) (e). 
Results are from representative experiments in triplicate. Data represent means ± s.e.m., *P < 
0.05 compared to NE = 0 (vehicle). (f) 3H uptake for A549 cells stimulated with neutrophil 
elastase in the presence or absence of 1.0 μM LY294002 or 10 μM U0126 for 60 min. Results 
are from a representative experiment in triplicate. Data represent means ± s.e.m. *P < 0.05. (g) 
Western blots of pAkt, Akt and β-actin for neutrophil elastase–exposed lysates of A549, 201T 
and LSL–K-ras cells. (h) Western blot of phospho-p44/p42 MAPK, p44/p42 MAPK, 
phosphorylated epidermal growth factor receptor (pEGFR) and β-actin for neutrophil elastase–
exposed A549 lysates. (i) Confocal images for early endosomal antigen-1 (EEA-1), caveolin-1 
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and neutrophil elastase from A549 cells exposed to Alexa Fluor 488–conjugated neutrophil 
elastase or vehicle. Nuclei were counterstained with DAPI. (j) 3H uptake for A549 cells 
stimulated with neutrophil elastase ± 40 μM dynasore. Results are from a representative 
experiment in triplicate. Data represent means ± s.e.m. *P < 0.05.  
Dependence of NE-induced proliferation upon PI3K was demonstrated using an inhibitor 
(LY294002), whereas inhibition of the MEK/ERK pathway (U0126) had no effect (Fig. 2f). NE 
exposure induced pAkt (Fig. 2g), as expected for a PI3K dependent process. Phospho-p44/42-
MAPK production was not affected (Fig. 2h). 
Alexa488-labeled NE was utilized to identify the site of NE and tumor cell interaction. 
Surprisingly, NE gained access to tumor cells beyond their plasma membrane. The enzyme was 
localized to early endosomal antigen-1+ (EEA1) endosomes (but not calveolae) (Fig. 2i), known 
to shuttle cargo from clathrin pits to other cellular locations [172]. Endosomal NE was required 
for cell proliferation, as inhibition of endosome formation (using dynasore[90]) prevented 
proliferation (Fig. 2j). 
Of growth factors known to activate PI3K, the PDGF/PDGFR complex is an attractive 
candidate to drive tumor cell proliferation. It's a potent inducer of pAkt via PI3K, is not found in 
lung epithelial cells, but is highly expressed in non-small cell lung cancer (NSCLC) [173]. Both 
the ligand and the receptor are produced in NSCLC thereby creating a potent autocrine loop for 
PI3K activation. LSL-K-ras tumors also express PDGF and PDGFR (Fig. 3a). 
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Figure 12. Neutrophil Elastase-induced proliferation is dependent upon PDGFR-PI3K signaling: 
(a) Representative images for PDGF and PDGFR immunohistochemistry (IHC) of LSL–K-ras
tumors. Insets, high magnification showing PDGF and PDGFR staining within cells with tumor 
morphology. (b) Western blots for PDGF, PDGFR-α, pPDGFR-α and β-actin from neutrophil 
elastase–exposed A549 cell lysates. Results from a representative experiment in triplicate. (c,d) 
Immunoprecipitation (IP) of p85 (c) and phospho-tyrosine p85 (d) from A549 cell lysates 
followed by western blotting (WB) for PDGFR-α. Membranes were stripped and probed for p85. 
(e) Representative blot for PDGFR-α after siRNA treatment with scrambled siRNA (SCR)
versus PDGFR-α–specific siRNA. (f) 3H uptake for PDGFR-α–silenced A549 cells exposed to 
neutrophil elastase or vehicle. Results from a representative experiment in triplicate. Data 
represent means ± s.e.m. 
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Treating A549 cells with NE at cell-proliferative concentrations didn't alter the quantity 
of PDGF, PDGFR, or p-PDGFR (Fig. 3b). NE-exposure did increase interaction (co-
immunoprecipitation) between the p85 subunit of PI3K and PDGFR (Fig. 3c,d). Gene silencing 
confirmed dependence of NE-induced proliferation on PDGFR (Fig. 3e,f). 
The PI3K axis is uniquely regulated within each cell type [69]. We reasoned that NE 
must degrade a homeostatic binding partner of p85. Loss of such a binding partner would create 
an opportunity for PDGF/PDGFR to recruit and activate p85. We identified a number of 
potential NE-substrates within the PI3K pathway, including IRS1, an adaptor protein known to 
bind p85 [46]. In fact, IRS1 and PDGF have been shown to differentially regulate PI3K activity 
in adipocytes, generating opposing effects on cell behavior despite activating the same p85 
subunit [72]. 
NE rapidly hydrolyzed IRS1 at 1:100 molar concentrations (Fig. 4a). Cell proliferative 
concentrations of NE eliminated IRS1 within A549 cells (Fig. 4b). Silencing of IRS1 gene 
expression induced tumor cell proliferation (Fig. 4c). Marked IRS1 over-expression reduced 
tumor cell growth and abrogated the proliferative effects of NE, confirming that IRS1 loss is a 
required event in this process (Fig. 4d). Hence, independent of NE, IRS1 is capable of regulating 
tumor cell proliferation. 
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Figure 13. Neutrophil Elastase colocalizes with and degrades IRS-1: (a) Western blot for IRS-1 
after incubation of recombinant IRS-1 protein with NE over a range of molar ratios. Con, 
control. (b) Western blots for IRS-1 and β-actin in neutrophil elastase–exposed A549 cell lysates. 
(c) 3H uptake for IRS-1–silenced (or SCR control) A549 cells subsequently exposed to
neutrophil elastase or vehicle. Results are from a representative experiment in triplicate. Data 
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represent means ± s.e.m. *P < 0.001 compared to control. **P < 0.05 compared to a neutrophil 
elastase concentration of 80 nM. Inset, western blot of IRS-1 in SCR siRNA– and IRS-1 siRNA–
treated lysates. (d) 3H uptake for IRS-1–overexpressing A549 cells exposed to neutrophil 
elastase or vehicle. Results are from a representative experiment in triplicate. Data represent 
means ± s.e.m. *P < 0.01. Inset, western blot of IRS-1 western blot in IRS-1 vector– and control-
treated lysates. (e) Confocal images for IRS-1 and neutrophil elastase from A549 cells exposed 
to neutrophil elastase (or vehicle) and labeled by antibody-mediated labeling. (f) Representative 
IRS-1 immunohistochemistry images from LSL–K-ras-Elane+/+ and LSL–K-ras-Elane−/− mice 14 
weeks after AdenoCre transduction. (g) IRS-1 western blot of tumor homogenates from both 
groups 14 weeks after AdenoCre transduction (n = 5). Results are presented as relative band 
density ± s.e.m. *P < 0.001. (h) Real-time PCR for Irs1 in tumor homogenates from both groups 
14 weeks after AdenoCre transduction (n = 4). Results are expressed as glyceraldehyde 3-
phosphate dehydrogenase CT/IRS-1 cycle threshold ± s.e.m. (i) Representative 
immunofluorescence images for pSer307 and pTyr608 IRS-1 from LSL–K-ras-Elane+/+ and 
LSL–K-ras-Elane−/− tumors 14 weeks after AdenoCre transduction. (j) Representative images of 
human lung adenocarcinoma specimens for NE = 2 and IRS-1 = 0 (Case 121t) and NE = 0 and 
IRS-1 = 3 (Case 649t) (see Online Methods for scale system). The empirical probability of 
discordance was 0.88, which was significantly greater than chance (0.5), P < 0.001. 
IRS1 isn't located on the cell surface nor sequestered in the ECM. Therefore, NE: IRS1 
interaction must occur within the cell, a distinct possibility given the trafficking studies presented 
in Fig. 2i. Confocal microscopy of NE-exposed A549 cells co-localized NE and IRS1 within 
tumor cells (Fig. 4e). Remarkably, Irs1 protein was significantly reduced in LSL-K-ras/Elane+/+ 
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compared to LSL-K-ras/Elane−/− tumors in vivo (Fig. 4f,g). However, Irs1 mRNA levels were 
equivalent between the two groups by qPCR (Fig. 4h), consistent with degradation of the protein. 
IRS1 has been reported to function in both pro-tumor and pro-host capacities [48]. The 
phosphorylation status of IRS1 may dictate behavior, with pTyr IRS1 functioning as a positive 
effector of growth factor and pSer producing a regulatory factor [174]. IRS1 accumulation in 
LSL-K-ras/Elane−/− tumors was predominantly serine-phosphorylated (Fig. 4i), consistent with 
this hypothesis. 
Han et al. reported that IRS1 staining was absent in 43.6% of Stage I NSCLC, correlating 
with increased tumor size [150]. We performed NE and IRS1 IHC on 38 human lung 
adenocarcinomas to confirm an inverse relationship between NE and IRS1 (Fig. 4j). We used 
likelihood ratio tests to demonstrate that the proportion of discordant views (NE and IRS1 were 
considered discordant when either one was present but the other was absent/faint in the same 
view) was statistically significant (P<0.001). 
These results may partially explain PI3K hyperactivity in NSCLC despite infrequent 
mutation in PTEN, the constitutive negative repressor of PI3K [69]. Our findings suggest that 
IRS1 is a key regulator of PI3K. We propose that the downstream consequences of p85 binding 
by IRS1 are fundamentally different (more homeostatic) than those for potent growth factors 
such as PDGFR. If IRS1 levels were depleted (NE-mediated degradation), or its ability to bind 
p85 altered (G972R polymorphism[175]), increased cancer susceptibility may result. In fact, 
G972R confers increased prostate cancer risk [176]. Aberrant autocrine loops (PDGF—PDGFR) 
would be required to significantly skew the net function of PI3K. Consistent with this 
hypothesis, NE didn't induce proliferation in lung epithelial cells (PDGFR−) but did in fibroblasts 
(PDGFR+) (Supplementary Fig. 3). 
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NE exists within neutrophil azurophil granules for rapid transit to phagolysosomes where 
it kills bacteria during acute infection [167, 168]. If “dumped” into ECM, NE causes tissue 
destruction. In the lung, unopposed NE degrades elastin resulting in emphysema [177]. NE may 
also cause cell death at high concentrations, but these concentrations are not likely achievable in 
vivo. At physiologic concentrations, NE was actively transported to a sub-cellular location and 
increased cell proliferation. The ability of a secreted proteinase to enter another cell and alter cell 
signaling represents a new concept in proteinase biology, and expands the list of both potential 
substrates and functions for proteinases. 
Small molecule inhibitors of NE have been developed for, although never adequately 
tested in, COPD. To demonstrate the plausibility of NE-inhibition as cancer therapy, we treated 
LSL-K-ras mice with the NE inhibitor, ONO-5046, or vehicle, for 14 weeks post-AdenoCre. 
Administration of the inhibitor reduced lung tumor growth by three-fold (P<0.05) 
(Supplementary Fig. 4). The results presented here might spur enthusiasm to test these agents in 
NSCLC, especially in light of the recent finding that emphysema predisposes to the development 
of lung cancer [178, 179]. NE may explain the link between the two diseases. As neutrophils and 
NE are recruited to the lungs of smokers to promote emphysema, sub-clinical nodules would 
become more aggressive. Hence, NE inhibition might be an attractive approach to treat both 
diseases, which currently account for ~300,000 deaths per year in the U.S. alone [158, 180]. 
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B.3 METHODS
B.3.1 Mice
Neutrophil elastase deficient mice (Elane−/−) on a C57BL6 background have been described 
elsewhere28. Lox-Stop-Lox K-rasG12D (LSL-K-ras) mice provided by Tyler Jacks have been 
described elsewhere4 and have subsequently been backcrossed into C57BL6 > five generations. 
Induction of mutant K-ras expression and the use of ONO-5046 is described in Supplementary 
Methods. All experiments described herein were approved by the Harvard Standing Committee 
for Animal Welfare or the University of Pittsburgh IACUC committee. 
B.3.2 Tissue Processing
The lungs were inflated with 10% buffered formalin at 25 cm H2O pressure via an intratracheal 
catheter for 10 min. The lungs were removed and fixed in 10% buffered formalin for 24 hr 
before embedding in paraffin. 
B.3.3 Histology and Immunohistochemistry
Serial mid-sagittal 5 μm sections were used for H&E staining and IHC. Tumor burden was 
reported as the percentage of lung area occupied by tumor (tumor area μm2/total area μm2) on 50 
different 10X sections per slide. IHC was performed as described4 using antibodies against 
PDGF (Upstate), PDGFRα/β (Upstate), IRS1 (Abcam) and Ki-67 (DAKO). The proliferative 
index was reported as the number of Ki-67 positive cells per tumor area. Lung tissue 
immunofluorescence was performed on frozen sections for phospho proteins not amenable to 
detection on routinely fixed tissues. Detailed methods are located in the Supplementary Methods. 
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Human lung adenocarcinoma cases (FFPE) obtained from the Lung SPORE tissue bank 
were subjected to NE and IRS1 IHC (Abcam). These studies were deemed “exempt” by the 
University of Pittsburgh Institutional Review Board. Four fields identified on the NE slide were 
imaged, and then the corresponding field in the IRS1 slide was imaged. Images were scored: NE, 
absent=0, present=2, 1-2 cells=1; and IRS1, absent=0, faint=1, present=2, heavy=3. NE=1 slides 
were excluded from the analysis. NE and IRS1 were considered discordant when whether one 
was present but the other absent/faint in the same view. For each tumor sample, the number of 
discordant views was modeled with a binomial distribution. Likelihood ratio tests determined 
whether the proportion of discordant views was significantly greater than one-half, the 
proportion that would be expected by chance. 
B.3.4 Cells
The human lung adenocarcinoma cell line A549 (K-ras mutant) was used for in vitro 
experiments (ATCC). Key experiments were duplicated in K-ras WT 201T lung adenocarcinoma 
cells (ATCC), and murine lung adenocarcinoma cell lines derived from LSL-K-ras tumors as 
previously described8. All cells were maintained in DMEM plus 10% FCS, 1X NEAA, and 1X 
penicillin/streptomycin. 
B.3.5 Thymidine Incorporation
Cells were plated at a concentration of 1×105 cells/well in 24-well plates before treatment with 
NE at concentrations from 4—400 nM (Elastin Products) for 60 min in serum-free media, 
washing with PBS, and incubation in serum-free media containing 1 μCi/mL of thymidine 
(Perkin Elmer) for an additional 18 hrs. Assays were terminated by washing with PBS, fixing 
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with 5% TCA, and washing with H2O. Cells were then dissolved in 300 mL 200 mM NaOH 
neutralized with equimolar HCl and transferred to scintillation vials. LY294002 (1.0 
μM)(Upstate), U0126 (10 μM)(Cell Signaling), PMSF (1 mM)(Sigma) and dynasore32 (40 
μM)(Sigma) were utilized in a subset of experiments. DMSO was the control vehicle for the 
LY294002, U0126, and dynasore experiments. Results from representative experiments in 
triplicate. All experiments were replicated at least three times. 
B.3.6 Confocal Microscopy
Confocal Microscopy was employed to determine the location of NE within tumor cells and to 
identify interaction with other proteins. Detailed procedures are located in the Supplementary 
Methods. 
B.3.7 Western Blotting
Standard 10% SDS-PAGE was performed followed by transfer of proteins to a nitrocellulose 
membrane. The following antibodies and dilutions were used: pAkt (1:250, Cell Signaling), Akt 
(1:500, Cell Signaling), p85 (1:500, Upstate), IRS-1 (1:500, Upstate), IRS-2 (1:500, Upstate), 
PDGF (1:250, Upstate), PDGFRα (1:250, Upstate), pPDGFRα (1:250, Upstate), p44/42-MAPK 
(1:500, Cell Signaling), phospho-p44/42-MAPK (1:500, Cell Signaling), and pEGFR (1:250, 
Cell Signaling). β-actin (1:1000, Cell Signaling) served as the endogenous control. All 
experiments performed in triplicate. All experiments were replicated at least three times. 
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B.3.8 Co-immunoprecipitation
Lysates from NE-treated A549 cells and controls were immunoprecipitated with anti-p85 or anti-
pTyr-p85 antibodies (Upstate) immobilized to protein A/G agarose resin according to 
manufacturer's instructions (Pierce). Following elution, the samples were subjected to Western 
blot using anti-PDGFRα (Upstate). All experiments performed in triplicate. All experiments 
were replicated at least twice. 
B.3.9 Protein Expression
IRS-1 protein was over-expressed in A549 cells using a lipofectamine transfection of pcDLSRα 
containing WT IRS1 [181]. Lipofectamine only transfection served as control. Western blotting 
confirmed IRS1 expression. 
B.3.10 siRNA
A549 cells were plated in 24-well plates at 5×104 cells/well. PDGFRα (Invitrogen), IRS-1 
(Dharmacon), or SCR siRNA (Invitrogen) (all 40 nM), were transfected using Lipofectamine per 
manufacturer's instructions (Invitrogen). Cells were washed with PBS 6 hrs later. Western blot 
analyses and thymidine incorporation assays were performed two days later. All assays were 
performed in triplicate and replicated at least three times in separate experiments. 
B.3.11 Statistics
Data are expressed as the mean value ± SEM. Simple pair-wise comparisons were analyzed 
using the student's t-test (two tailed distribution with two sample equal variance). For multiple 
comparisons, one-way ANOVA with Newman-Keuls post-test was employed. A P value of 
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<0.05 was considered significant. The Kaplan-Meier survival curve analysis employed a log-
rank test. 
B.4 SUPPLEMENTARY FIGURES AND METHODS
Supplementary Figure 1. Decreased lung metastases in Elane-/- mice: (a) Primary tumor weights 
of Elane+/+ and Elane-/- mice 31 days after subcutaneous injection of 1x106 LLC cells. N=4 mice 
per group. Bars ± SEM. *P<0.05. (b) Gross LLC lung metastases (#) for Elane+/+ and Elane-/- 
mice. N=3-4 mice per group. Bars ± SEM. *P<0.05. (c) Representative histology from WT and 
Elane-/- mouse lungs 31 days post-LLC flank injection.  
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Supplementary Figure 2. NE-induced tumor cell proliferation requires catalytic activity: (a) 
Thymidine incorporation of A549 cells exposed to NE, heat-inactivated NE, or NE mixed with 
PMSF (serine proteinase inhibitor). Results from a representative experiment in triplicate. Bars ± 
SEM. *P<0.05. Wester blots of IRS-1, pAkt, Akt, and B-actin from A549 lysates exposed to (b) 
heat-inactivated NE or (c) NE/PMSF mixture.  
85 
Supplementary Figure 3. NE induces proliferation in fibroblasts, but not lung epithelial cells: 
Thymidine incorporation of (a) primary mouse lung epithelial cells and (b) primary mouse lung 
fibroblasts exposed to NE or vehicle control for 60 min. Results from a representative 
experiment in triplicate. Bars ± SEM. *P<0.05.  
86 
Supplementary Figure 4. NE-inhibition reduces lung tumor growth in vivo: (a) Lung tumor area 
for LSL-K-ras mice 14 weeks post-AdenoCre exposure treated with ONO-5046 (NE-inhibitor) 
or vehicle control. N=6 each group. Bars ± SEM. *P<0.05. (b) Representative images for ONO-
5046 and vehicle control treated mouse lungs.  
Supplementary Table 1: Description of tumor lesions by number, location, and type. Data 
expressed as mean values Bars ± SEM. N=5 mice each group *P<0.05 (ANOVA). 
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Activation of mutant K-ras in vivo. K-ras activation was achieved in vivo by 
administering 5x106 pfu titer adenoviral Crerecombinase (AdenoCre, University of Iowa) 
intratracheally to mice at eight weeks of age as previously described4 . Briefly, the mice were 
anesthetized with avertin and received the titer of adenovirus intranasally in two administrations 
of 62.5 l volume ten minutes apart. WT mice receiving AdenoCre and LSL-K-ras mice receiving 
vehicle only (Opti-MEM) served as controls. As these mice did not develop tumors, this data has 
not been included in the manuscript. The mice were age and sex matched for all experiments. An 
initial cohort of mice was treated with AdenoCre and followed to establish a life survival curve. 
This experiment was terminated when all of the mice in the WT group had died, as per our 
IACUC protocol. Repeat experiments were terminated at pre-determined time points of 8, 14, 
and 20 weeks. 
Administration of NE-inhibitor. An additional cohort of LSL-K-ras mice was 
administered AdenoCre and subjected to IP injection of an NE-inhibitor (ONO-5046, Elaspol, 
50mg/kg/day, ONO Pharmaceutical, Japan) or vehicle, six days/wk for 14 wks. 
Bronchoalveolar lavage fluid (BALF). BALFwas obtained by inserting a 22g IV catheter 
into the trachea and lavaging the lungs with 0.75 mL saline x 4. BAL fluid was centrifuged at 
3000 rpm for 3 min. The pellet was treated with red blood cell lysis buffer and resuspended in 
1.0 mL saline to determine cellular content. Neutrophil, macrophage, lymphocyte, and total cell 
counts were measured using a hemocytometer and cytospins stained with Hema3 (Fisher).  
Lung tissue immunofluorescence. Lung tissue was inflated with 2% PFA for 1 hr. Fixed 
tissue was immersed in 2.3 M sucrose in PBS overnight at 4oC and frozen in liquid nitrogen-
cooled 2-methylpentane. Sixmm sections wereaffixed to charged slides (Fisher). Tissue was 
washed with PBS and blocked in 2% BSA for 30 min at RT. Primary antibodies (phospho-Akt 
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(Cell Signaling) phospho-p44/42 MAPK (Cell Signaling), phospho-IRS1 (Tyr941 and Ser307, 
Upstate) all diluted 1:100 in 0.5% BSA in PBS (PPB) buffer were added to sections 1 hr at RT. 
Sections were washed in PPB Buffer then fluorescently tagged secondary antibodies (goat anti-
rabbit-Cy3, Jackson ImmunoLabs), diluted 1:1000 in PPB buffer, were added tosections for 1 hr 
at RT. Tissue was washed in PPB buffer then PBS before counterstaining nuclei with Hoechst 
33342. Tissue was coverslipped using Gelvatol. Confocal images were obtained on an Olympus 
Fluoview 1000 confocal microscope using an oil immersion 40x objective. Quantification of 
signal was performed using MetaMorph. Six different tumors in each mouse were imaged using 
a single slice confocal image at 400x and Cy3 signal was evaluated relative to non-immune gated 
control. Results reported as relative fluorescence intensity.  
Visualizing NE uptake by A549 cells. A549 cells were plated at a concentration of 2.5 x 
104 cells/mL on 12mm circular coverslips within 24-welltissue plates. NE (1 mg, Elastin 
Products) was covalently labeled with Alex-488 following the manufacturer’s instructions 
(Invitrogen). The cells were exposed to Alexa-488-labeled NE (0 –200 nM) for 60 min, rinsed 
with PBS and fixed for 60 min in 2% PFA. Cells were washed in labeling buffer (PBG; 0.5% 
BSA, 0.15% glycine in PBS). After 30 min 20% non-immune goat serum block in PBG, cells 
were incubated with primary antibody; rabbit anti-human EEA1 (Abcam) or rat anti-human 
caveolin-1 (Abcam); in PBG for 3 hrs, washed with PBG, and incubated with fluorescently 
labeled secondary antibodies (goat anti-rat or goat anti-rabbit Cy3, Jackson Immunolabs) in PBG 
for 60 min. Cells were washed in PBG, then in PBS followed by a 30 sec stain with Hoechst 
nuclear stain. Cells were then washed in PBS and coverslipped using Gelvatol. In cases where 
non-labeled NE was used, cells were treated as described above, but immuno-labeled with mouse 
anti-human NE (Chemicon) and rabbit anti-human IRS1 (Upstate). Goat anti-mouse Cy3 
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(Jackson Immunolabs) and goat anti-rabbit Alexa488 (Invitrogen) were used as secondary 
antibodies. All confocal images were taken using an inverted Olympus Fluoview 1000 
microscope fitted with a 100x oil immersion objective and digitally zoomed 2x prior to acquiring 
the image.  
Isolation of lung epithelial cells. Primary mouse lung epithelial cells were harvested and 
cultured from C57BL-6 mice, as previously described [182, 183] and grown on collagen IV 
coated 24-well plates. Briefly, lungs were perfused with 10ml 0.9% saline. Dispase (3ml) was 
instilled into the lungs via intratracheal catheter followed immediately by 0.5mLlow melt 
agarose at 45°C. Lungs were immediately covered with ice for 2min. The lungs were then 
removed and incubated in 1ml dispase for 45min at 25°C. Lungs were subsequently transferred 
to a 60-mmculture dish containing 7ml of HEPES-buffered DMEM and 100U/ml DNAse I. Lung 
tissue was filtered through progressively smaller cell strainers (100 and 40μm) and nylon gauze 
(20μm). Cells were collected by centrifugation at 130g for 8min (4°C) and placed on 
prewashed/antibody pre-coated 100-mm tissue culture plates (coated for 24-48 h at 4°C with 
42μg CD45 and 16μg CD32 in PBS). After incubation for 1-2 h at 37°C, the cells were gently 
panned from the plate and collected by centrifugation. The cells were then allowed seven days to 
differentiate prior to experimentation.  
Isolation of murine lung fibroblasts. Primary mouse lung fibroblasts were isolated from 
C57BL/6 mice, as previously described [184]. Briefly, the lungs were perfused with 10mL sterile 
saline and placed in ice cold DMEM with 10 IU/ml penicillin, 10 g/ml streptomycin. Each set of  
lungs was minced into small pieces and placed on scratched 100mm2 culture dishes. The pieces 
of lung were allowed to adhere to the plate for 10 min then gently submerged in 10 mL of 
growth media (DMEM with 10% FBS, penicillin, streptomycin). The explants were removed 
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from the dishes after 7 days in culture, after which the plates were cultures for 7 additional days. 
The fibroblasts were subsequently passaged to T-75 flasks and cultured on 96-well plates.  
Lewis Lung Carcinoma (LLC) cells. Lewis Lung Carcinoma (LLC) cells were utilized in 
the spontaneous metastasis model as previously described [185]. Briefly, 1x106 LLC cells were 
injected subcutaneously into the right flank of C57BL6 and NE-/- mice. Primary tumors were 
removed and weighed 21-days after injection. The number of gross lung metastases (visible on 
the pleural surface to the naked eye) was tabulated over a time course. 
ELISA. BALF was obtained as above. Samples were normalized by volume. The levels 
of TGFα, VEGF, PDGF-AA, PDGF-AB, and PDGF-BB were determined using the 
commercially available Quantikine kits (R&D Systems) as per the manufacturer’s instructions. 
Results of PDGF-AB and PDGF-BB were not shown as each was below detection limits of the 
assay. Each sample was performed in duplicate, n=5 samples 
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C.1 SIGNIFICANCE
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disorder characterized by fibroblast 
proliferation and myofibroblast differentiation. Although neutrophil accumulation within IPF 
lungs has been negatively correlated with outcomes, the role played by neutrophils in lung 
fibrosis remains poorly understood.  We have previously demonstrated that neutrophil elastase 
(NE) promotes lung cancer cell proliferation, and hypothesized that it may have a similar effect 
on fibroblasts. In the current study, we show that NE-/- mice are protected from asbestos induced 
lung fibrosis. NE-/- mice displayed reduced fibroblast and myofibroblast content when compared 
to controls. NE directly promotes both lung fibroblast proliferation and myofibroblast 
differentiation in vitro as evidenced by proliferation assays, collagen gel contractility assays, and 
αSMA induction. Furthermore, αSMA induction occurs in a TGF-ß independent fashion. 
Treatment of asbestos recipient mice with ONO-5046, a synthetic NE antagonist, reduced 
hydroxyproline content. Thus, the current study points to a key role for neutrophils and NE in the 
progression of lung fibrosis.  Lastly, the study lends rationale to using NE inhibitory approaches 
as a novel therapeutic strategy for patients with lung fibrosis. 
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C.2 INTRODUCTION 
Idiopathic Pulmonary Fibrosis (IPF) is a rapidly progressive and debilitating lung disease, the 
most common of several types of interstitial lung diseases that affect humans.  There are 
currently no effective therapies for IPF patients, such that this progressive disorder confers an 
average survival duration of just three to five years, and accounts for >20,000 deaths annually, in 
the US alone [186]. Clearly a better understanding of the molecular pathogenesis of lung fibrosis 
will be required to develop new and effective therapies for IPF subjects [133].  
A considerable amount of research has focused on the apparent culprit cell in lung 
fibrosis, the myofibroblast [187]. The lungs are well stocked with fibroblasts, which maintain the 
extensive extracellular matrix (ECM) scaffolding required for oxygen exchange. Unfortunately, 
these lung fibroblasts can take on a hyperfunctioning phenotype with wound healing 
characteristics. Such myofibroblasts are highly contractile and release substantial quantities of 
ECM proteins, such as collagen, that results in scarring of the lung, or lung fibrosis. The 
hallmark of the myofibroblast is the expression of alpha-smooth muscle actin (αSMA), which 
confers exaggerated contractile properties to myofibroblasts [188]. Despite extensive study, the 
mechanisms by which lung fibroblasts differentiate into myofibroblasts remain poorly 
understood. It is certainly clear that transforming growth factor-ß (TGF-ß) can induce 
myofibroblast formation.  Mechanistically, TGF-ß, through interaction with its receptor, induces 
the generation of phosphorylated mothers against decapentaplegic homolog 3 (pSMAD3) from 
SMAD3, which then functions as the transcription factor for the production of αSMA [189]. It 
remains unclear if other factors within the lung environment promote myofibroblast 
differentiation, and if these factors do so in a TGF-ß-dependent or -independent fashion.  
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Our group has focused on the role of neutrophils in lung fibrosis.  There exists data from 
human cohorts supporting a role for PMNs in the pathogenesis of IPF [190]. Bronchoalveolar 
lavage (BAL) fluid content of both neutrophils and of neutrophil elastase (NE) has been shown 
to correlate with disease severity in IPF [134, 191, 192].  NE is a neutrophil derived serine 
proteinase with broad substrate specificity, including most components of the ECM [193].  
However, the major physiologic function of NE is matrix independent. NE is an essential means 
of host defense against pulmonary [167], and other, infections. Once neutrophils have 
phagocytosed bacteria, they rapidly shuttle NE into the phagolysosomes, where it degrades key 
bacterial cell wall structures, resulting in lysis of bacteria [194].  
Once in the extracellular space, NE is capable of degrading essentially all of the ECM 
proteins found within the lung, including collagens (types I-III), laminin, entactin, fibronectin, 
type IV collagen, and elastin [195].  NE is best known for its ability to cleave elastic fibers 
within the lung, which is a key event in the pathogenesis of emphysema [177, 196]. Although it 
has been reported that NE promotes the development of lung fibrosis [197], the mechanisms 
remain unclear, and may not involve the processing of ECM substrates.  Accordingly, treatment 
of bleomycin-exposed animals with the serine leukocyte proteinase inhibitor (SLPI, a naturally 
occurring NE inhibitor) reduced the extent of lung injury [198].  Interestingly, the low dose of 
SLPI used in this study did not completely abrogate NE enzymatic activity in the lung, 
suggesting that the mechanism of action was not the simple inhibition of NE-mediated tissue 
destruction.  
Because IPF lungs display enhanced fibroblast content and function, we postulated that 
NE could be involved in the proliferation and differentiation of these cells. We have previously 
shown that NE promotes cellular proliferation in multiple different lung cancer cell lines [88]. 
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Recently, other groups have reproduced these findings in breast cancer cells [199], as well. 
Notably, NE accomplishes this by entering tumor endosomes via classic clathrin pit mediated 
endocytosis, where it ultimately targets intracellular substrates within the cytosol [200]. The 
most notable of these is the insulin receptor substrate-1 (IRS-1), a key mediator of 
phosphoinositol-3 kinase (PI3K) signaling [201].  We detected increased pAkt production and 
cellular proliferation in A549 lung adenocarcinoma cells (and others) in the absence of IRS-1, 
whether from NE treatment or IRS-1 silencing [88]. Interestingly, IPF fibroblasts have been 
demonstrated to display enhanced PI3K activity in vivo [202]. The purpose of the current study, 
therefore, is to determine if NE promotes fibroblast proliferation in vitro and in vivo, and to 
identify the mechanisms by which this occurs. Here, we show that NE does in fact induce 
fibroblast proliferation and, surprisingly, also promotes myofibroblast differentiation, in a novel, 
TGF-ß-independent fashion.  
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C.3 MATERIALS AND METHODS
C.3.1 Material
Human neutrophil elastase (NE, also known as human leukocyte elastase) was purified from 
human sputum and purchased from Elastin Products Co. (Owensville, MO).  ONO-5046 was 
obtained from ONO Pharmaceutical (Osaka, Japan). Crocidolite asbestos was obtained from 
Andy Ghio (NIEHS).  
C.3.2 Mice
NE-/- mice on a pure C57BL/6 background (>10 generations backcrossing) were generated as 
previously described [177], and provided by Steve Shapiro (University of Pittsburgh).  Age and 
sex-matched wild-type C57BL/6 mice (Jackson, Bar Harbor, ME) were used as the controls. All 
experiments were approved by the University of Pittsburgh Institutional Animal Care and Use 
Committee. 
C.3.3 Asbestos induced lung injury
Age and sex matched C57BL/6 and NE-/- mice between 8-10 weeks of age were anesthetized 
with 2.5% avertin and intubated using a standard prone technique. By way of an endotracheal 
catheter, the mice received either 0.1 mg crocidolite asbestos or 0.1 mg titanium dioxide (TiO2, 
inert control particulate). Animals were examined at either 7-days or 14-days post asbestos 
treatment. All mice were weighed daily for the duration of the experiment. At the time of 
harvest, bronchoalveolar lavage (BAL) was performed on each mouse, the right lung was tied off 
and excised, and the left lung was inflated with 10% buffered formalin at 25cm H20 pressure for 
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10 min, followed by additional formalin fixation for 24 hrs in a 50 cc conical tube. The right lung 
was flash frozen in liquid nitrogen, homogenized on ice in CHAPS buffer (50 mmol/L Tris-HCl 
(pH 7.4), 150 mmol/L NaCl, 10 mmol/L CHAPS), with proteinase inhibitors. The lung 
homogenate was placed in glass vacuoles for hydroxyproline analysis.  
C.3.4 Hydroxyproline assay
Lung homogenate samples were dried in glass vacuoles in a 110C oven for 24 hrs. Acid 
hydrolysis was completed by adding 6M HCl. Vials were vacuumed, sealed and incubated under 
anoxic conditions for 24 hours at 110C. After drying, the samples were assayed for 
hydroxyproline using chloramine-T [203], as previously described.  
C.3.5 Histology
Formalin fixed lungs (generated above) were embedded in paraffin.  Sections were subjected to 
routine H&E and Masson’s Trichrome staining. These images were used to measure the fibrosis 
index, or the proportion of high-powered lung fields showing evidence of fibrotic involvement. 
The fibrosis index was generated by scoring fields with >50% alveolar tissue and terminal 
bronchioles according to the following scale:  0 = no fibrosis, 1 = 0-25%, 2 = 26-50%, 3 = 51-
75%, and 4 = 76-100%. A histologic index score was assigned to each sample by dividing the 
sum of the scores of each field by the total number of scored fields.  Lung fibroblasts were 
quantified using fibroblast specific protein-1 (FSP-1) immunostaining (rat-anti mouse antibody, 
ab27957, 1:100 dilution, Abcam, Cambridge, MA) on mid-sagittal sections using a standard 
avidin-biotin HRP technique in which 3,3’-diaminobenzidine was the chromogenic substrate. 
Results were expressed as the average count from ten hpf per slide, in which only fibrotic lesions 
98 
were tabulated. In order to identify myofibroblasts via immunofluorescence staining, lungs were 
inflated with and embedded in OCT (Sakura, Torrance, CA) prior to sectioning.  Six micron mid-
sagittal lung tissue sections were adhered to glass slides and fixed with 2% paraformaldehyde 
(PFA) for 30 min. Tissue was permeabilized by treating with 0.1% Triton X-100 (Sigma, St. 
Louis, MO) for 5 min and subsequently blocked with 1% BSA for 45 min. Nuclei were stained 
with 1mg/mL Hoescht and cover glass adhered with gelvatol mounting media. Tissue was 
stained with anti-smooth muscle actin (1:200, Sigma A5228) and anti-S100A4 (1:200, ab27957, 
Abcam). Primary antibodies were removed and sections washed three times with PBS before 
addition of fluorochrome-conjugated secondary antibodies, anti-mouse-Alexa488 and anti-
rabbit-Alexa595 (both 1:500, Invitrogen). Stained tissue was imaged using a Fluoview 1000 
Confocal Microscope (Olympus, Center Valley, PA) and all laser settings were obtained using 
secondary antibody-only control sections.  
C.3.6 Flow Cytometry
Lung tissue was homogenized into a single cell suspension using a one-hour digestion with 1 
mg/mL collagenase type IV and 0.5 mg/mL DNase in DMEM followed by gentle mechanical 
disruption and passage through a 22-gauge needle. Cells were pre-treated with Fc block (BD 
Biosciences, San Jose, CA) and then stained with CD45-FITC (eBioscience, San Diego, CA) for 
one hr at 4C. Cells were then fixed and permeabilized using Cytofix/Cytoperm reagents 
according to manufacturer’s instructions (BD Biosciences). Following permeabilization, cells 
were incubated with unconjugated anti-S100A4 (ab27957) and αSMA-PE (R&D Systems, 
Minneapolis, MN) for one hr at 4C. Cells were then washed and stained with anti-rabbit-APC 
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(Invitrogen, Grand Island, NY) in order to bind unconjugated anti-S100A4. Cells were analyzed 
using a FacsCalibur flow cytometer (BD Biosciences) using CellQuest Pro acquisition software. 
C.3.7 Cells
LL47 human lung fibroblasts were obtained from ATCC and cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) + 10% fetal bovine serum (FBS). Primary mouse lung fibroblasts 
(PMF) were isolated from C57BL/6 mice, as previously described [183], with modifications. Six 
to eight week old female mice were euthanized before perfusing the right ventricle with 10 mL 
normal saline to remove blood from the lungs. The lungs were then removed and placed in ice-
cold DMEM with 10 IU/mL penicillin and 10 µg/mL streptomycin. The lungs were minced into 
small pieces and placed on scratched 100 mm2 culture dishes.  The pieces of lung were allowed 
to adhere to the plate for 10 min then gently submerged in 10 mL DMEM + 10% FBS. The 
explants were removed from the dishes after seven days in culture, after which the plates were 
cultured for an additional seven days. The fibroblasts were subsequently passaged to T-75 flasks. 
The identical procedure was performed using the lungs from insulin receptor substrate-1 (IRS-
1fl/fl) mice [91] and WT mice on the same genetic background (129/SvJ), with the addition of 
1x105 pfu (MOI 100:1) adenoviral cre recombinase (AdCre, University of Iowa Vector Core) on 
day 14 to both IRS-1fl/fl and IRS-1+/+ cultures for the purpose of removing the floxed allele.  
C.3.8 Neutrophil elastase treatments
Lung fibroblasts (both LL47 and PMF, in separate experiments) were exposed to NE. The cells 
were plated at 1x105 cells/well in 24-well plates in serum free media for 24 hrs prior to NE 
exposure. NE was administered over a dose course (1nM-40nM) for one hour. In some 
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experiments, NE treatments were accompanied by 30 min pre-treatment with either PI3K 
inhibitor (LY294002, 50µM, Cell Signaling, Danvers, MA) or type I activin receptor-like kinase 
(ALK) receptor inhibitor (SB431542, 10µM, Sigma) and with continued exposure during the 
course of the NE treatment. In other experiments, NE was inactivated either by heating to 100C 
for 15 minutes or by conjugating with 5mM of the serine proteinase inhibitor 
phenylmethylsulfonyl fluoride (PMSF, Sigma) at 37C for one hour. Cells were subsequently 
washed, lysed, and stored at -80C for additional analyses.  
C.3.9 Confocal microscopy
LL47 fibroblasts were plated on tissue culture-treated coverslips (Thermo Fisher, Pittsburgh, PA) 
in 24-well plates, allowed to adhere overnight, and transferred to serum-free media for 24 hr. NE 
was fluorescently labeled using the Alexa Fluor 488 protein labeling kit (Invitrogen) according 
to manufacturer’s instructions.  Cells were treated with Alexa Fluor 488-NE (4nM) for one hr, 
immediately fixed in 2% PFA in PBS, and permeabilized with 0.1% Triton X-100. Cells were 
co-stained for early endosomal antigen-1 (EEA-1, 1:200, Abcam), phalloidin (1:200, Invitrogen), 
or αSMA (A5228, 1:200, Sigma). Donkey anti-rabbit 594 or donkey anti-mouse 488 (Invitrogen) 
antibodies were used as the secondary antibodies. The identical procedure was repeated using 
Alexa488-labeled trypsin.  Cells were imaged using an Olympus Fluoview 1000 upright confocal 
microscope.  Ten fields per preparation were quantified to determine the percentage of cells 
displaying intracellular Alexa488 staining.  
101 
C.3.10 Fibroblast proliferation assays
Fibroblast proliferation in response to NE treatment was assessed using MTS (Promega) cell 
viability assays. LL47 or PMF were plated in 96-well plates (4,000 cells/well) and placed in 
serum-free DMEM for 24 hrs prior to treatment. Cells were treated with media or NE (0 to 40 
nM) for 60 min at 37C (both with and without PMSF and heat inactivation). Wst-1 and MTS 
assays were performed according to manufacturer’s instructions and absorbance readings were 
obtained. All experiments were performed in triplicate and replicated at least three times. Results 
are expressed as % control +/- SEM.  
C.3.11 Would healing (scratch) assay
LL47 fibroblasts were plated on 24 well polystyrene plates and grown to confluence in growth 
media. Straight wounds were created with a p200 pipet tips, washed, and treated with NE over a 
dose range. After 1 hr, the cells were washed with PBS. Images were captured using a 4x 
objective with phase contrast (Nikon, Melville, NY) at time = 0, 18, and 24 hrs. Wound areas 
were quantified using NIS-Elements Software (Nikon).  
C.3.12 Gel contractility assay
Type I rat tail collagen (BD Biosciences) was rapidly mixed with 2x105 LL47 cells in serum free 
media at a final concentration of 1.8 mg/mL. Cells were treated with NE at the indicated 
concentrations. The gels were allowed to solidify in a 24 well plate for 20 min at RT and were 
then gently dissociated from the walls of the plate and incubated in serum free media at 37C with 
5% CO2 for 72 hrs.  Plates were imaged using an Omega imaging system (UltraLum, Claremont, 
CA) and areas were quantified using ImageJ software (NIH).  To determine the number of 
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fibroblasts present in the gel matrix, at 72 hrs gels were digested with 0.25 mg/mL collagenase 
type XI (Sigma) for 1 hr at 37C and the resultant cell pellet was counted using a hemocytometer.  
C.3.13 Immunoblotting
Proteins were separated using standard 10% SDS-PAGE followed by transfer of protein to 
PVDF membranes. Membranes were blocked for 2 hrs at RT or overnight at 4 degrees in 5% dry 
milk in PBS-tween.  Primary antibodies were incubated overnight at 4C followed by secondary 
antibody incubation (rabbit or mouse IgG HRP conjugated, 1:5000) for 1 hr at RT. The 
following primary antibodies were used: αSMA (1:250) from Abcam and IRS-1 (1:1000), Akt 
(1:2000), pAkt (1:1000), p38MAPK (1:2000), phospho-p38MAPK (1:1000), pSMAD3 (1:1000), 
SMAD2/3 (1:2000), GAPDH (1:2000), all from Cell Signaling Technology.  
C.3.14 Statistics
All data were reported as mean value +/- SEM.  Statistical significance was determined using 
either Student’s t-test (two-tailed distribution with two-sample equal variance) or ANOVA 
followed by Tukey’s post-test using Graphpad Prism software (Graphpad, San Diego, CA).  A P-
value of < 0.05 was considered significant.  
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C.4 RESULTS
C.4.1 NE-deficient mice are protected from asbestos induced lung fibrosis
To determine if NE promotes asbestos induced lung injury, we subjected NE-/- mice and 
C57BL/6 control mice to the intratracheal administration of 0.1 mg crocidolite asbestos, or TiO2 
vehicle control. Both groups of mice were studied at 7 and 14 days post asbestos treatment. 
Intratracheal delivery of asbestos generated a characteristic fibrotic response within the lungs of 
C57BL/6 mice that was evident on both H&E and Masson’s trichrome staining at the 14-day 
time point (Figure 1A). Additionally, hydroxyproline measurements similarly demonstrated a 
statistically significant increase in hydroxyproline content in asbestos treated C57BL/6 mice 
when compared to TiO2 controls (Figure 1B) at day 14, a finding that was not present at the 
earlier time point. In contrast, NE-/- mice were completely protected from asbestos induced lung 
fibrosis. Although there was a scant amount of lung fibrosis present on histological sections, the 
hydroxyproline content in the lungs of NE-/- asbestos treated mice was not statistically different 
from the TiO2 treated C57BL/6 or NE-/- mice (Figure 1B). Accordingly, histological scores of 
H&E and trichrome stained slides revealed that the fibrotic index was significantly reduced in 
asbestos treated NE-/- mice as compared to asbestos treated C57BL/6 mice (Figure 1C).  Since 
there has been some speculation that NE may play a role in inflammatory cell trafficking to the 
lung [204], we analyzed the cellular content of BAL fluid from both groups. As shown in Figure 
1D, there was increased BAL inflammation in the asbestos treated mice, though there were not 
differences observed between WT and NE-/- mice. 
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Figure 14. NE-/- mice are protected from asbestos induced lung fibrosis: WT and NE-/- mice 
were treated with 0.1 mg crocidolite asbestos or TiO2 control.  (A) Representative images from 
H&E (10X) and Masson’s Trichrome (20X) stained lung sections 14 days after asbestos 
treatment. (B) Hydroxyproline content was measured at days 7 (left panel) and 14 (right panel). 
N=6-8 per group.  (C) Fibrosis index was generated according to the criteria described in 
Materials and Methods. N=6-8 per group.  (D) BAL neutrophil, macrophage, and lymphocyte 
counts for 14 days post-TiO2 treatment (left panel; N=6); day 7 post-asbestos treatment (middle 
panel; N=8), and day 14 post-asbestos treatment (right panel, N=8). Installations were performed 
at least two times and the data was pooled. All data presented as mean value +/- SEM.  Two-
tailed Student’s t-test was used to compare differences between groups. *P<0.05.  
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C.4.2 Reduced fibroblast content in NE-/- mice
Since fibroblasts and myofibroblasts are essential mediators of disease pathogenesis in lung 
fibrosis, we quantified these cells in asbestos treated WT and NE-/- mice. FSP-1 stained sections 
demonstrated a doubling of fibroblast content in WT asbestos treated mice as compared to the 
NE-deficient arm, which was statistically significant (Figure 2A).  We attempted to measure 
αSMA expression using immunofluorescence staining. We were able to identify some FSP-
1/αSMA double-positive cells in WT asbestos treated mice, whereas these cells were virtually 
undetectable in asbestos treated NE mice (Figure 2B). However, this methodology, and the 
sparse nature of these cells identified using immunofluorescence did not offer the ability to 
reliably quantify such cell types.  
We performed flow cytometry in order to better quantify the number of fibroblasts and 
myofibroblasts present in asbestos induced lung injury. Similar to the finding reported for FSP-1 
immunohistochemsitry (IHC), we observed an approximate doubling of fibroblasts (by FACS 
analysis) present in WT asbestos treated mice as compared to NE-/- mice, even after gating 
specifically on the CD45- population (in order to exclude any FSP-1+ macrophages) (Figure 2C-
D).   
To quantify lung fibroblasts that had adopted the pro-fibrotic myofibroblast phenotype, we 
measured the proportion of lung fibroblasts in each treatment group that expressed αSMA by 
FACS.  This involved a permeabilization step, as αSMA is an intracellular protein. Once again, 
the data showed that there were approximately twice as many myofibroblasts, defined as CD45-
FSP1+αSMA+ cells, in the lungs of C57BL6 asbestos treated mice when compared to asbestos 
treated NE-/- mice (Figure 2C-E). We also quantified pericytes and smooth muscle cells (CD45-
FSP1-αSMA+ cells) and fibrocytes (Figure 2F-G). Fibrocyte content was determined by 
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eliminating CD11c+ and F4/80+ cells (macrophages) from the CD45+FSP1+ population.  We 
were unable to identify significant differences in these populations, suggesting that the major cell 
types affect by NE deficiency are fibroblasts and myofibroblasts.  
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Figure 15. Decreased fibroblast and myofibroblast content in NE-/- mice: WT and NE-/- mice 
were treated with 0.1 mg crocidolite asbestos or TiO2 control and studied 14 days later.  (A) 
Representative images and quantification of IHC staining for FSP-1+ cells. Results expressed as 
positive cells/hpf from ten fields per mouse (N=8 each group).  (B) Representative confocal 
images from αSMA (green), FSP-1 (red), and DAPI (blue) stained frozen lung sections. Laser 
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voltages were set such that the secondary antibody-only controls exhibited no fluorescence. (C) 
Representative flow cytometric dot plots of single cell suspensions obtained from day 14 
asbestos-treated whole lungs denoting percentages of fibroblasts (CD45-FSP1+) and 
myofibroblasts (CD45-FSP1+αSMA+). Gates were set according to isotype controls as illustrated. 
Total cell numbers of (D) fibroblasts (CD45-FSP1+), (E) myofibroblasts (CD45-FSP1+αSMA+), 
(F) pericytes/smooth muscle cells (CD45-FSP1-αSMA+) and (G) fibrocytes
(CD45+FSP1+CD11c-F4/80-) were obtained by multiplying cell percentages by the absolute 
whole lung cell count obtained by hemacytometer counts (N=7 mice per group). Dot plots in (G) 
have been gated on CD45+FSP1+ cells. All data presented as the mean value +/- SEM. FACS 
experiments were performed twice with one representative experiment shown. Two-tailed 
Student’s t-test was used to compare differences between the two groups. *P<0.05. 
C.4.3 NE induces fibroblast proliferation
Prior studies by our group established the ability of NE to promote the proliferation of lung 
cancer cells. Based upon the in vivo phenotype above, we suspected that NE might be 
functioning in a similar capacity with respect to fibroblast proliferation. We exposed both the 
LL47 human fibroblast cell line and PMFs (primary murine fibroblasts, from C57BL/6 mice) to 
a dose range of NE. The results showed that NE induced fibroblast proliferation at modest 
concentrations of NE, very similar to the dosages that induce proliferation in cancer cells (Figure 
3A-D). We suspect that similar concentrations of NE are encountered in vivo, although this has 
proven difficult to determine experimentally. NE is rarely “dumped” into the extracellular space, 
but rather released from granules in quantum microbursts to overcome the anti-proteinases 
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prevalent in the extracellular compartment [171]. Therefore, the concentrations encountered at 
the cell surface are likely to be modest. 
The mechanism by which NE induces fibroblast proliferation appears to be quite similar to 
that previously described for cancer cell proliferation. Exposure of NE to fibroblasts for one hour 
results in complete loss of insulin receptor substrate-1 (IRS-1), a key mediator of PI3K activity 
(Figure 3E-F).  We suspect that this is a direct proteolytic effect of NE, as we have previously 
shown that NE degrades recombinant IRS-1 protein at 1:100 molar ratios, and co-localizes with 
IRS-1 within cancer cells. At the same time that IRS-1 loss is noted, we observed a substantial 
increase in cellular pAkt production, again, similar to our findings in cancer cells (Figure 3E-F). 
High concentrations of NE (40nM) produce the opposite effect. Whereas modest concentrations 
of NE induced proliferation in lung cancer cells and breast cancer cells, high concentrations 
induce cell death. In this case, the high concentrations simply damage the cell membrane, which 
results in cellular lysis. The absence of loading control observed on the Western blots (GAPDH) 
at high NE concentration is simply a reflection of reduced cell content. NE-mediated 
proliferation (low dose) and toxicity (high dose) require catalytic activity, as both heat- and 
PMSF-inactivated NE fail to reproduce these effects (Figure 3B-C).  
A unique aspect of NE-induced cellular proliferation is that it requires entry into the target 
cell beyond its plasma membrane. We were able to localize Alexa488-labeled NE within early 
endosomal antigen-1 (EEA-1) positive endosomes (Figure 3G-H). This finding is specific for 
NE, as Alexa488-labeled trypsin was unable to enter the endosomes.  Based upon our findings, 
and those of others, NE has been demonstrated to enter multiple different cancer cell lines 
including lung and breast, and now fibroblasts as well. As is the case for fibroblasts, NE-induced 
cellular proliferation requires the presence of its catalytic domain [88, 200].  
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The loss of IRS-1 is a key event in NE-induced fibroblast proliferation. To demonstrate this, 
we generated IRS-1-deficient fibroblasts. This was accomplished by making PMFs from IRS-1fl/fl 
mice and WT littermate controls and treating them with AdenoCre (1x105 pfu, MOI 100:1) to 
remove the floxed allele. IRS-1-deficient fibroblasts generated in this way display increased 
proliferation when compared to controls (Figure 3I-J). 
 
 
 
 
 
 
 
 
111 
Figure 16. NE induces fibroblast proliferation: MTS proliferation assay for LL47 cells treated 
with (A) NE, (B) heat-inactivated NE, (C) PMSF-inactivated NE, and  (D) PMF fibroblasts 
treated with NE at the indicated concentrations (N=12 wells per treatment). Western blots 
performed on (E) LL47 and (F) PMF fibroblast cell lysates for IRS-1, pAkt, Akt, p38MAPK, 
phospho-p38MAPK, and GAPDH following NE treatment for one hr at the indicated 
concentrations. (G) Alexa 488-labeled NE (4nM) and trypsin was incubated with LL47 
fibroblasts for 60 min and washed with PBS. Cells were stained with anti-EEA1 (red) and 
counterstained with DAPI (blue) and imaged using confocal microscopy. Magnification = 
1200X. (H) The percentage of cells in each field, which contain co-localized NE and EEA1 
(yellow) was quantified for both trypsin-Alexa488 and NE-Alexa488.  Ten confocal fields per 
condition (containing at least 75 cells in total) were imaged and quantified.  (I) MTS-
proliferation assay for WT and IRS-1fl/fl fibroblasts, conducted at 24 (left panel) and 48 (right 
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panel) hours after an overnight treatment with adenoviral Cre-recombinase (MOI=100:1) (n=4 
for each condition, representative of two independent experiments). (J) Western blot depicting 
knockdown of IRS-1 in primary fibroblasts described in (I). Lysates were prepared at t=0 prior to 
conducting the 24- and 48-hour proliferation experiments. All data presented as the mean value 
+/- SEM. Each study was performed twice with one representative experiment shown. Two-
tailed Student’s t-test was used to compare differences between groups. *P<0.05. 
C.4.4 NE promotes myofibroblast differentiation
As demonstrated above, asbestos treated NE-/- mice display both reduced fibroblast and 
myofibroblast content. Therefore, we tested the concept that NE could promote myofibroblast 
differentiation. NE treatment facilitated wound closure in a simple scratch assay, using the same 
cell proliferative concentrations as above (Figure 4A-B). To more clearly demonstrate the 
contractile phenotype of NE exposed fibroblasts, we performed a collagen gel contractility assay. 
Once again, cell proliferative concentrations of NE enhanced fibroblast contractility, resulting in 
statistically significant changes in gel area (Figure 4C-D). Furthermore, modest concentrations of 
NE reduced gel area to a similar extent as witnessed with TGF-ß, serving as a positive control. 
The major biochemical feature of myofibroblasts is αSMA production. As suggested from the 
results of the scratch and contractility assays, exposure of fibroblasts to NE induces the 
expression of αSMA by western blot (Figure 4F). The contractile nature of NE treated 
fibroblasts is best illustrated by confocal microscopy. The αSMA expressing stress fibers 
identified in NE treated fibroblasts were not evident in the control fibroblasts (Figure 4E). 
NE-induced αSMA production is associated with significant increases in pSMAD3 
production. This is not surprising, given that this is the most commonly reported mechanism for 
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αSMA gene transcription. Most interestingly, NE-induced αSMA production appears to be 
independent of TGF-ß signaling, as concomitant administration of SB431542, a TGF-ß receptor 
antagonist, failed to abrogate αSMA production in the setting of NE exposure, although it did 
eliminate αSMA production in the absence of NE (Figure 4F). We suspected that the increased 
generation of pAkt induced by NE treatment might be related to the observed changes in αSMA 
production. However, this did not turn out to be the case, as co-administration of LY294002 
(PI3K inhibitor) failed to abrogate αSMA production, though it did eliminate pAkt production 
(Figure 4F). Also of note, IRS-1 apparently does not play a significant role in NE-induced 
myofibroblast differentiation, as IRS-1-deficient fibroblasts fail to upregulate αSMA production 
(not shown). 
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Figure 17. NE promotes myofibroblast differentiation: (A-B) Wound healing assay for LL47 
fibroblasts plated on scratched tissue culture plastic and treated with NE (0, 4, or 8nM) for one 
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hr. Data are mean value of % wound closure +/- SEM from a representative experiment in 
triplicate.  (C-D) LL47 fibroblasts were embedded in a type I collagen matrix in 24-well plates. 
Gels were treated with NE (0-40nM) or TGF-ß for one hr. Data are mean value of gel area +/- 
SEM (N=8 wells per condition) pooled from two independent experiments. All NE and TGF-ß 
treatment groups are significantly different than untreated wells at each time point as indicated 
by the three asterisks. (E) LL47 fibroblasts were incubated with 4nM NE for one hr.  Cells were 
stained for αSMA (green) and counterstained with phalloidin (red) and DAPI (blue). 
Magnification = 600X.  (F) Representative Western blots for αSMA, pAkt, pSMAD3, and 
GAPDH for NE treated fibroblasts in the presence and absence of the TGF-ß inhibitor SB431542 
(10µM, upper panels) and the PI3K inhibitor, LY294002 (50µM, lower panels). TGF-ß treated 
fibroblasts in the presence and absence of the TGF-ß inhibitor SB431542 are also depicted 
(middle panels). One-way ANOVA was performed to determine statistical significance between 
groups. *P<0.05.  
C.4.5 ONO-5046 inhibits asbestos induced lung fibrosis in mice 
To demonstrate the therapeutic relevance of NE activity in the setting of lung fibrosis, we 
repeated our asbestos induced lung injury studies using a synthetic small molecule inhibitor of 
elastase. ONO-5046 has previously been shown to be an effective antagonist of both mouse and 
human NE. We previously used this agent to demonstrate that it could reduce tumor growth in 
the Lox-Stop-Lox (LSL)-K-ras mouse model of lung adenocarcinoma. Here, we administered a 
large cohort of mice (N=8 each group) either daily IP injections of ONO-5046 (100mg/kg) or 
vehicle control. After two weeks, the lungs were subjected to histological analysis and 
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hydroxyproline assay. As depicted in Figure 5, ONO-5046 significantly reduced lung fibrosis, as 
evidenced by a reduction in hydroxyproline content and fibrosis index.  
 
 
Figure 18. ONO-5046 reduces asbestos induced lung injury: (A) Hydroxyproline assay for 
asbestos recipient C57BL/6 mice treated with ONO-5046 (100 mg/kg) or vehicle control IP daily 
for 14 days. N=8 mice per group. This study was performed twice with one representative 
experiment shown. Data are mean value +/- SEM. *P<0.05.  (B) A fibrosis index was generated 
according to the criteria described in Materials and Methods. N-14 mice per group, pooled from 
two independent experiments. (C) Representative H&E images (10X) of the lungs from ONO-
5046 treated and vehicle control mice. Two-tailed Student’s t-test was used to compare 
differences between groups.  *P<0.05. 
117 
C.5 DISCUSSION
Fibroproliferative disorders of the lung are surprisingly common and essentially untreatable 
diseases that result in substantial morbidity and mortality. Although the quantity and quality of 
lung fibroblasts have long been known to drive lung fibrosis, the origin of these cells remains 
unclear. Among the possibilities are:  local proliferation of lung fibroblasts, recruitment of bone 
marrow derived cells (fibrocytes) to the lung, and the constellation of myofibroblast 
differentiation covered under epithelial-mesenchymal transition (EMT) [205]. With respect to 
proliferation of lung fibroblasts, the factors that drive their proliferation both in vitro and in vivo 
remain unclear. Since IPF subjects also display robust neutrophil infiltration within their lungs, 
we hypothesized that NE may contribute to the proliferation of lung fibroblasts in the setting of 
IPF disease pathogenesis. 
Using NE-/- mice, we were able to show that the increase in lung fibroblast content 
induced by the administration of intratracheal asbestos is largely dependent upon elastase. 
Additionally, the differentiation of a subset of these fibroblasts into myofibroblasts is promoted 
by the presence of NE. As one would suspect, the quantity of fibroblasts and myofibroblasts 
correlates with the severity of lung fibrosis, as demonstrated here using trichrome staining and 
hydroxyproline assay. We used in vitro assays to more directly show that NE can induce 
fibroblast proliferation and myofibroblast differentiation. Mechanistically, NE drives fibroblast 
proliferation by targeting IRS-1, which results in PI3K hyperactivity, as has been shown in 
cancer cells. The ability of NE to promote myofibroblast differentiation does not appear to 
involve the observed increase in PI3K activity, as the use of a PI3K inhibitor failed to abolish 
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αSMA production. Similarly, the ability of NE to promote myofibroblast differentiation does not 
involve IRS-1, as IRS-1 silencing, in and of itself, is not sufficient for αSMA induction.  
NE was first reported to promote cellular proliferation in psoriasis, a benign neoplastic 
disorder of keratinocytes [206]. More recently, we have reported that NE promotes cellular 
proliferation of lung cancer cells, both in vitro and in vivo [88]. To accomplish this, NE enters 
tumor endosomes in lung cancer cells via classic clathrin pit mediated endocytosis and targets 
intracellular substrates [200]. The ability of NE to enter cancer cells while inducing their 
proliferation has been replicated in other cell types, most notably in breast cancer cells [199].  
The NE-IRS-1 axis, described here, has emerged as a key pathophysiologic mechanism in a 
variety of disease states. In addition to our findings with respect to lung cancer and lung fibrosis, 
Talukdar and colleagues reported NE-mediated loss of IRS-1 protein in hepatocytes [207]. 
During a study of glucose intolerance in mice, they showed the complete loss of IRS-1 from 
hepatocytes in mice fed a high fat diet. Interestingly, high fat diet was associated with increased 
neutrophilic inflammation within the liver. When the experiment was repeated using NE-/- mice, 
there was no decrease in hepatocyte IRS-1 content, despite equal amounts of neutrophil influx.  
IRS-1 is a signaling adaptor protein best known for its canonical signaling downstream 
from the insulin receptor (IR) and insulin-like growth factor receptor (IGF-1R), where it 
mediates glucose metabolism [45]. However, IRS-1 adapts signals for numerous pathways, 
including PI3K, mitogen activated protein kinase (MAPK), and various cytokine receptors [47]. 
The impact of IRS-1 loss on intracellular signaling is dependent upon the cell of origin and 
disease microenvironment. As such, both increases and decreases in PI3K output (pAkt 
production) have been reported in the setting of IRS-1 deficiency [208]. Determining the detailed 
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mechanisms by which IRS-1 regulates intracellular signaling cascades is an ongoing area of 
investigation in our laboratory. 
The exact means by which NE promotes myofibroblast differentiation also remains an 
area of active investigation within our group. The ability of NE to induce αSMA production 
occurs in a SMAD dependent but TGF-ß independent fashion. Both SMAD and TGF-ß-
independent mechanisms promoting myofibroblast differentiation have been reported. SMAD 
independent generation of the myofibroblast phenotype typically involves PI3K signaling and 
the participation of a downstream effector molecule, p21 activated kinase-2 [209]. We had 
initially suspected that PI3K was operative in our cells, given the observed increases in pAkt, but 
were unable to demonstrate dependence on PI3K using a synthetic antagonist, LY294002. The 
effects of NE on fibroblasts are likely pleiotropic, and PI3K activity may be important in the 
migratory phenotype (via Rac1) but not the contractile phenotype [210]. Another identifiable 
effect of NE is the induction of F-actin. Additional studies are underway in our laboratory to 
examine the roles of recently described myocardin-related transcription factor (MRTF) and 
serum-response factor (SRF)-mediated myofibroblast differentiation program, which is 
potentially TGF-ß independent, and thus represents an attractive potential mechanism for our 
observed phenotype [211]. TGF-ß independent αSMA production has also been reported, most 
notably for found in inflammatory zone-1 (Fizz-1). Fizz-1 has specifically been shown to 
contribute to lung fibrosis and can induce αSMA completely independently of TGF-ß [212]. The 
mechanism by which this occurs, as with the case for NE here, remains unknown.  
Treatment options are scarce for IPF subjects. Traditional immune suppressive therapies, 
such as systemic corticosteroids and azathioprine, alone or in combination with N-acetylcysteine, 
have failed to demonstrate any clear benefit [213]. The results presented here carry therapeutic 
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relevance. Inhibition of NE, using a synthetic antagonist, largely abrogated the development of 
asbestos induced lung fibrosis. This approach highlights the possibility of using non-traditional 
approaches to limit fibroblast growth and function, which holds promise as a potential 
therapeutic strategy for lung fibrosis patients.  
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